RoboSense Technology Co., Ltd
速騰聚創科技有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock code : 2498

2026

INTERIM REPORT

CONTENTS

CORPORATE INFORMATION

DIRECTORS

Executive Directors

Dr. Qiu Chunxin
(Chairman of the Board and Chief Scientist)
Mr. Liu Letian *(Chief Technology Officer)*
Mr. Qiu Chunchao (Chief Executive Officer)

Non-executive Director

Dr. Zhu Xiaorui *(Scientific Advisor)*

Independent Non-executive Directors

Mr. Liu Ming
Mr. Ng Yuk Keung
Ms. Yang Rixin

AUDIT COMMITTEE

Mr. Ng Yuk Keung *(Chairperson)*
Mr. Liu Ming
Dr. Zhu Xiaorui

REMUNERATION COMMITTEE

Ms. Yang Rixin *(Chairperson)*
Mr. Liu Ming
Dr. Zhu Xiaorui

NOMINATION COMMITTEE

Dr. Qiu Chunxin *(Chairperson)*
Ms. Yang Rixin
Mr. Ng Yuk Keung

ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE

Dr. Qiu Chunxin *(Chairperson)*
Mr. Liu Letian
Mr. Qiu Chunchao

AUTHORIZED REPRESENTATIVES

Mr. Qiu Chunchao
Ms. Lau Yee Wa

JOINT COMPANY SECRETARIES

Mr. Lau Wing Kee
Ms. Lau Yee Wa

REGISTERED OFFICE

Maples Corporate Services Limited
P O Box 309
Ugland House
Grand Cayman
KY1-1104, Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

Building 9
Zhongguan Honghualing Industry
Southern District
1213 Liuxian Avenue, Taoyuan Street
Nanshan District, Shenzhen, PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1912, 19/F
Lee Garden One, 33 Hysan Avenue
Causeway Bay, Hong Kong

AUDITOR

PricewaterhouseCoopers
Certified Public Accountants and
Registered Public Interest Entity Auditor

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS

Maples Fund Services (Cayman) Limited
PO Box 1093
Boundary Hall, Cricket Square
Grand Cayman KY1-1102, Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong

PRINCIPAL BANKS

CMB Wing Lung Bank
Citibank N.A., Hong Kong branch
Bank of China Limited, Shenzhen Nantou sub-branch

LEGAL ADVISOR AS TO HONG KONG LAWS

Linklaters
11/F, Alexandra House
Central, Hong Kong

COMPANY WEBSITE

www.robosense.ai/en

CHIEF EXECUTIVE OFFICER'S STATEMENT

Dear Shareholders,

We are pleased to present the interim report for the six months ended June 30, 2026.

2026 marks a pivotal inflection point for RoboSense, as it sets out on a new chapter that will define the next transformative decade.

In 2024, we resolved to fully embrace Physical AI and articulated a new corporate vision: to evolve into a leading robotics-technology platform company. Following two years of consistent execution, RoboSense's product matrix has expanded beyond LiDAR to cover three core incremental categories built for embodied robots: "Eyes", "Skin" and "Muscles". This contributes to both robot bodies and data-collection systems, and commercial deliveries will be rolled out in phases from the third quarter of this year.

In the first half of the year, the Company achieved total revenue of RMB1.020 billion, representing a year-on-year increase of 30.2%; our total sales volume of LiDAR products reached 719,200 units, representing a year-on-year increase of 169.6%. Of this amount, the sales volume of our ADAS LiDAR products reached 436,600 units, representing a 98.0% year-on-year increase; the sales volume of LiDAR products for robotics and others reached 282,600 units, representing a 510.4% year-on-year increase. Having functioned as a secondary growth engine, robotics-related business has now matured into a genuine pillar of the Company's overall business.

The customer base, chip capabilities, supply chain system and mass production experience developed through our LiDAR business are being rapidly redeployed across new product lines. Space Camera, tactile sensors and joint modules, when adopted by the existing robotics-customer base and deployed in use cases, will further boost per-robot content value and deepen customer stickiness.

Within the LiDAR industry, competition has shifted to the semiconductor-chip architecture layer. Our in-house developed chips have also entered mass production and delivery. E2 – our second-generation fully solid-state digital LiDAR powered by the "Peacock" chipset – commenced volume shipments. Deliveries of related products are projected to surpass 200,000 units during the second half of this year. Also, the first automotive-project powered by the "Phoenix" chipset will achieve SOP in the fourth quarter of this year.

Growth in the automotive business remains in line with expectations and it will remain the foundational bedrock for the Company's automotive-grade engineering capabilities, semiconductor chip mass production, supply-chain governance and large-scale manufacturing expertise.

In the second half of the year, we will continue to iterate and improve our SPAD-SoC chips built on the "EOCENE" architecture, and launch more advanced digital products. We will drive our Space Camera to complete additional customer testing and project conversions. In parallel, visual-tactile and MEMS tactile sensors are scheduled to commence product deliveries in the third quarter. For our "muscles" product line, volume delivery will commence in the fourth quarter.

Looking ahead to 2027, as our robotics product matrix continues to improve and mass-production projects roll out successively, our robotics business is expected to further expand its customer reach, delivery scale and revenue contribution, injecting stronger growth momentum into the Group's profitability.

Historically, RoboSense has been defined by its LiDAR offerings. Today, we are re-defining the Company around robotics. RoboSense will focus its resources on developing the most critical "eyes" and "hands" for the upper body of an embodied robot. Our goal is to enable robots to see clearly, sense precisely, grip firmly and complete real-world tasks.

Qiu Chunchao
Chief Executive Officer
September 23, 2026

KEY FINANCIAL AND OPERATIONAL HIGHLIGHTS

KEY FINANCIAL HIGHLIGHTS

	For the six months ended June 30,	
	2026	2025
	(Unaudited)	(Unaudited)
	(RMB in thousands, except for percentage)	(RMB in thousands, except for percentage)
Revenue	**1,019,749**	783,207
Gross profit	**222,189**	203,136
Gross margin	**21.8%**	25.9%
Operating loss	**(171,774)**	(197,149)
Net loss	**(159,947)**	(148,606)
(Loss)/Profit for the period attributable to:		
Owners of the Company	**(161,219)**	(150,980)
Non-controlling interests	**1,272**	2,374

	As of June 30,	As of December 31,
	2026	2025
	(Unaudited)	(Audited)
	(RMB in thousands)	(RMB in thousands)
Total assets	**5,273,933**	5,265,682
Total liabilities	**1,721,146**	1,460,243
Total equity	**3,552,787**	3,805,439

KEY OPERATIONAL HIGHLIGHTS AND RECENT DEVELOPMENT

- For the second quarter of 2026 ("**2026Q2**"), the Group's sales volume of LiDAR products, LiDAR products for ADAS applications, and LiDAR products for robotics and others amounted to approximately 388,900, 291,800 and 97,100 units, respectively, representing an increase of 145.8%, 135.7% and 182.3%, respectively, as compared to the second quarter of 2025 ("**2025Q2**").

- For the six months ended June 30, 2026, the Group's sales volume of LiDAR products, LiDAR products for ADAS applications, and LiDAR products for robotics and others amounted to approximately 719,200, 436,600 and 282,600 units, respectively, representing an increase of 169.6%, 98.0% and 510.4%, respectively, as compared to the same period of 2025.

- Our gross profit increased by 9.4% to RMB222.2 million in the first half of 2026 from RMB203.1 million in the same period of 2025. Our overall gross margin decreased to 21.8% in the first half of 2026 from 25.9% in the same period of 2025.

- As of June 30, 2026, our design wins for mass production of LiDAR products with 36 automotive OEMs and Tier 1 suppliers had increased to 186 vehicle models, and we had achieved SOP for 81 vehicle models with 17 of the aforementioned automotive OEMs and Tier 1 suppliers.

- As of the date of this report, our design wins for mass production of LiDAR products have further increased to 194 vehicle models. Amongst these, 37 design wins were awarded by overseas OEMs and Sino-foreign joint venture OEMs, which cover markets in Japan, North America and Europe.

- At the World Artificial Intelligence Conference (WAIC) held in July 2026, RoboSense launched E2, its second generation high-precision ultra-wide-FOV digital fully solid-state LiDAR, powered by our in-house developed "Peacock" chip. Featuring a digital fully solid-state scanning architecture, E2 delivers high precision, broad FOV, compact size and strong reliability, supporting humanoid, quadruped and lawn-mowing robots, to advance commercial deployment of Physical AI across multiple sectors.

- Unveiled on July 30, 2026, Xiaomi SkyNomad N90 Max is fitted exclusively with RoboSense's digital fully solid-state LiDAR, representing Xiaomi's first mass-production vehicle with digital fully solid-state LiDAR.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW AND OUTLOOK

Overview

RoboSense is an AI-driven robotic technology company that supplies advanced and reliable incremental components and solutions for the robotics industry. We are committed to becoming “a global leader in robotic technology platforms,” and our mission is to make “Safer world, Smarter life.” RoboSense was established in 2014 with its headquarters located in Shenzhen, China. We currently employ over 2,200 professionals and employees who are working in our offices in various countries and regions, including Shanghai, Suzhou and Hong Kong in China, Stuttgart in Germany, and Detroit and Silicon Valley in the United States.

Business Review

2026 represents a pivotal inflection point for RoboSense, as we embark on a new chapter that will define the next transformative decade for the Company.

Back in 2024, the Company further embraced Physical AI and articulated a new corporate vision: to evolve into a leading robotics-technology platform company. On the product front, beyond our core LiDAR portfolio, we set out to deliver a broader suite of components and end-to-end solutions built for Physical AI. From a commercial perspective, we target expansion into new industry verticals, extending our footprint from automotive into industrial, consumer, embodied-intelligence and other application domains.

Following two years of consistent execution, RoboSense has refined its market positioning through the lens of a robotics-technology platform and defined its category boundaries and business structure under an entirely new framework.

Product Categories: “Eyes”, “Skin”, and “Muscles”

RoboSense’s product matrix has expanded beyond LiDAR to cover three core component categories built for embodied robots: “Eyes”, “Skin” and “Muscles”.

Eyes

Complementing our depth-sensing LiDAR portfolio, we have introduced the Space Camera as an entirely new product category. Driven by our in-house-developed, industry-leading high-performance SPAD semiconductor chip, the Space Camera enables native alignment of colour and depth information – an industry first – delivering RGB-D outputs with millimetre-level precision. For near-field manipulation tasks performed by embodied robots, the Space Camera supports accurate object identification under variable ambient-light conditions and within low-texture environments.

Over the past two years, RoboSense has developed and iterated a full line-up of Space Camera products, including variants purpose-built for robot-head and robot-wrist deployment (head-mounted and wrist-mounted configurations). Besides being applied on robot's main body, Space Camera also plays a key role in isomorphic data-collection systems, helping these systems to capture ultra-high-quality data.

Our Space Camera product series made successive public debuts with multiple live demonstrations, including presentations at the 2026 IEEE International Conference on Robotics and Automation (ICRA) — the premier academic robotics conference held in Vienna in early June and at the WAIC held in July this year. We have entered into long-term, in-depth co-development partnerships for the Space Camera with several leading global technology firms, robotics enterprises and top-tier research laboratories. To date, we have secured volume orders from selected leading global enterprises. Customer deliveries of Space Camera units are scheduled to commence by the end of the third quarter of 2026, with full-scale volume roll-out planned for 2027. We are confident that the Space Camera will emerge as one of the core growth drivers for our 2027 financial performance.

Skin

RoboSense has completed the development of two "skin" product categories: visual-tactile sensor and MEMS tactile sensor.

Leveraging more than a decade of our accumulated optics expertise, we have substantially simplified the optical path architecture of visual-tactile sensor, reducing computation requirements while achieving extreme miniaturization – with size small enough to fit into the fingertip of a dexterous hand. We have also utilized our proprietary MEMS technology and industrialization capabilities on developing MEMS tactile sensor. The product is designed to address the drift and hysteresis issues of conventional electronic skin, physically capturing high-resolution, array-based multi-axis force information, and is deployed in the finger pads and multiple other locations.

Beyond being applied on the robots' main body, our "skin" products are equally effective in data-collection systems – working together with our "eye" products to enable high-quality data collection for hand-eye coordination. These two "skin" products have completed the product development stage, and also have entered the commercialization stage: our first enterprise-grade mass-production project will commence the commercial product deliveries by the end of September this year, with SOP in the fourth quarter this year.

Muscles

Relying on our capabilities of developing miniaturized-motor for LiDAR products, we have completed the development of our joint modules – the “muscles”. Our joint module products can solve the issues of low precision and poor control efficiency caused by low motor torque density. Moreover, our product can ensure longer useful life.

Our first “muscle” products have also completed the development stage and, like our “skin” products, entered the commercialization stage. We have received initial procurement demand for our joint modules in the tens of thousands of units, and we plan to start volume delivery in the fourth quarter of this year.

As such, as a supplier of “core incremental components of robot”, RoboSense has completed the first-phase convergence of product matrix upgrade. We have expanded beyond LiDAR and, with the hand-eye coordination system at the core, will continue to serve both robot bodies and data-collection systems through our three product lines: the “eyes”, the “skin” and the “muscles”.

Revenue Structure: Robotics Becoming a Real Pillar

From a revenue-contribution perspective, our robotics business continues to deliver transformative breakthroughs.

In 2024, the revenue split between our ADAS and robotics businesses stood at approximately 9:1. For the first half of 2026, revenue generated from our robotics segment accounted for nearly half of the Group’s total revenue from product sales. The robotics business has maintained a comparatively solid gross-margin profile. It drove nearly all of our incremental revenue generation in the first half of 2026 and has emerged as a primary source of gross profit from product sales. Having functioned as a secondary growth engine, robotics has now matured into a genuine pillar of the Company’s overall business.

This progress underpins a self-reinforcing commercial cycle for our robotics business. Our early robotics-focused LiDAR engagements have allowed the Company to build customer base and bolster supply-chain capabilities. New product lines – including the Space Camera, tactile sensors and joint modules – are poised to drive higher per-robot content value across our existing robotics-customer base and deepen customer stickiness.

The Company’s strategic roadmap is steadily unfolding, driving a notable shift in our business mix. We are no longer dependent on any single product line or solely reliant on the automotive market. With an expanding portfolio of product categories and growing number of robotics programmes moving into mass production, we remain optimistic regarding the ongoing evolution of our future revenue and profit base.

LiDAR and the ADAS Business

Notwithstanding cyclical headwinds in the automotive industry this year, LiDAR adoption has continued to increase rapidly.

On the product front, LiDAR-industry competition has shifted to the semiconductor-chip architecture layer. In April this year, we unveiled the EOCENE SPAD-SoC architecture alongside two chipset families: Phoenix and Peacock. In the third quarter of 2026, E2 – our second-generation fully solid-state LiDAR powered by the Peacock chipset – commenced volume shipments. Under current project timelines, Peacock-based product deliveries are projected to surpass 200,000 units during the second half of 2026. The Phoenix chipset is scheduled for its first automotive-project SOP in the fourth quarter of this year.

Gross-margin performance within our ADAS business faced headwinds during the first half of this year, stemming from supply-chain pressures driven by broad AI-fueled market demand, which tightened availability and lifted pricing for components. Nevertheless, underlying market demand for LiDAR products in this segment has remained broadly in-line with our expectations.

In the first half of 2026, sales volume of our ADAS LiDAR products totalled 436,600 units, representing a 98.0% year-on-year increase. In the second quarter of 2026, standalone sales volume of ADAS LiDAR products reached 291,800 units, growing 135.7% year-on-year.

As at the end of June 2026, the Company had established mass-production partnerships with 36 automotive OEMs and Tier 1 suppliers. We secured cumulative design wins covering 186 vehicle models, of which 81 models have achieved SOP. Notably, our newly-added Xiaomi Auto project has progressed to volume-delivery phase.

The ADAS business will continue its growth trajectory and remains the foundational bedrock for the Company's automotive-grade engineering capabilities, semiconductor chip mass production, supply-chain governance and large-scale manufacturing expertise.

Business Outlook

In second half of 2026, we will continue to iterate and improve our SPAD-SoC chips built on the EOCENE architecture. Drawing on these, and ongoing chip-level upgrades, the Company will keep launching industry-leading digital LiDAR products to satisfy the market's rapidly rising demand for LiDAR solutions.

For our “eye” product line – the Space Camera – we will complete additional customer testing and drive further project conversions. Turning to our “skin” product line, visual-tactile and MEMS tactile sensors are scheduled to commence product deliveries in the third quarter of 2026. For our “muscles” product line, volume delivery will commence in the fourth quarter of 2026.

In 2027, our growing suite of robotic products is expected to drive further customer wins and expanded product deliveries, which in turn will help fuel broader-based growth across the robotics business. As our robotics business scales, it will also serve as an ongoing driver for the Company’s profitability.

Historically, RoboSense has been defined by its LiDAR offerings. Today, we are re-defining the Company around robotics. While computing power and Models enable robots to think, it is robotic eyes and hands that determine real-world task execution. RoboSense will not manufacture every single robot component. Instead, we will focus our resources on developing the most critical upper-body robotic building blocks: “eyes” and critical components of hands (“skin” & “muscles”). Our goal is to enable robots to see clearly, sense precisely, grip firmly and complete real-world tasks.

Since June 30, 2026 and up to the date of this interim report, there was no material adverse change in our financial or trading position or prospects and there was no event that would materially affect the information set out in the unaudited interim condensed consolidated financial statements in this interim report.

FINANCIAL REVIEW

Six months ended June 30, 2026 compared to six months ended June 30, 2025

The following table sets forth the comparative figures for the six months ended June 30, 2026 and 2025.

	For the six months ended June 30,	
	2026	2025
	(Unaudited)	(Unaudited)
	(RMB in thousands)	(RMB in thousands)
Revenue	**1,019,749**	783,207
Cost of sales	**(797,560)**	(580,071)
Gross profit	**222,189**	203,136
Research and development expenses	**(346,452)**	(308,712)
Sales and marketing expenses	**(73,827)**	(56,894)
General and administrative expenses	**(93,686)**	(78,317)
Net reversal of impairment losses on financial assets	**848**	4,066
Other income	**45,691**	39,789
Other gains/(losses) – net	**73,463**	(217)
Operating loss	**(171,774)**	(197,149)
Finance income – net	**19,877**	50,108
Share of net (loss)/profit of associates accounted for using the equity method	**(8,085)**	621
Loss before income tax	**(159,982)**	(146,420)
Income tax benefits/(expenses)	**35**	(2,186)
Net loss	**(159,947)**	(148,606)
(Loss)/profit attributable to		
Owners of the Company	**(161,219)**	(150,980)
Non-controlling interests	**1,272**	2,374

The following table sets forth the comparative figures as of June 30, 2026 and December 31, 2025.

	As of June 30, 2026 (Unaudited) (RMB in thousands)	As of December 31, 2025 (Audited) (RMB in thousands)
Total current assets	**4,283,583**	4,637,880
Total non-current assets	**990,350**	627,802
Total assets	**5,273,933**	5,265,682
Total current liabilities	**1,377,712**	1,206,923
Total non-current liabilities	**343,434**	253,320
Total liabilities	**1,721,146**	1,460,243
Total equity	**3,552,787**	3,805,439
Total equity and liabilities	**5,273,933**	5,265,682

Revenue

	For the six months ended June 30,	
	2026	2025
	(Unaudited)	(Unaudited)
	(RMB in thousands)	(RMB in thousands)
Revenue from:		
Products	**958,003**	721,026
Solutions	**17,220**	51,174
Services and others	**44,526**	11,007
Total	**1,019,749**	783,207

Our total revenue increased by about 30.2% to RMB1,019.7 million in the first half of 2026 from RMB783.2 million in the same period of 2025, primarily attributable to the increase in sales of products. Revenue generated from sales of products increased by about 32.9% to RMB958.0 million in the first half of 2026 from RMB721.0 million in the same period of 2025, mainly because the sales volume of LiDAR products increased by about 169.6% to approximately 719,200 units in the first half of 2026 from approximately 266,800 units in the same period of 2025. Revenue from services and others increased by about 304.5% to RMB44.5 million in the first half of 2026 from RMB11.0 million in the same period of 2025, primarily attributable to income recognized from a technology development service project in the first half of 2026.

Cost of Sales

Our cost of sales increased by about 37.5% to RMB797.6 million in the first half of 2026 from RMB580.1 million in the same period of 2025, primarily driven by the increase in sales of products in the first half of 2026.

Gross Profit and Gross Margin

Gross profit increased by about 9.4% to RMB222.2 million in the first half of 2026 from RMB203.1 million in the same period of 2025. Overall gross margin decreased to 21.8% in the first half of 2026 from 25.9% in the same period of 2025. The decline in overall gross margin was mainly attributable to the decrease in average unit selling price of LiDAR product and the increase in raw material procurement costs in the first half of 2026.

R&D Expenses

Our R&D expenses increased by about 12.2% to RMB346.5 million in the first half of 2026 from RMB308.7 million in the same period of 2025. The increase was mainly attributable to the increase in employee benefit expenses, and the increase in raw materials and consumables used in developing new semi-conductor chips and new perception sensor products to be applied in ADAS application and robotics. Our R&D expenses excluding share-based compensation as a percentage of revenue reduced to 31.2% in the first half of 2026 from 36.3% in the same period of 2025.

Sales and Marketing Expenses

Our sales and marketing expenses increased by about 29.8% to RMB73.8 million in the first half of 2026 from RMB56.9 million in the same period of 2025. The increase was primarily due to the increase in employee benefit expenses, professional service fees and advertising and promotion costs. Our sales and marketing expenses excluding share-based compensation as a percentage of revenue increased slightly to 6.8% in the first half of 2026 from 6.7% in the same period of 2025.

General and Administrative Expenses

Our general and administrative expenses increased by about 19.6% to RMB93.7 million in the first half of 2026 from RMB78.3 million in the same period of 2025. The increase was primarily due to the increase in employee benefit expenses, professional service fees and office and freight expenses, as well as traveling and other expenses. Our general and administrative expenses excluding share-based compensation as a percentage of revenue reduced to 8.8% in the first half of 2026 from 9.3% in the same period of 2025.

Other Income

Our other income increased by about 14.8% to RMB45.7 million in the first half of 2026 from RMB39.8 million in the same period of 2025. The increase was primarily due to the increase in interest income from structured and time deposits and value-added tax refund, partially offset by the decrease in government grant subsidies.

Other Gains/(Losses) – Net

Other gains/(losses) improved from a loss of RMB0.2 million in the first half of 2025 to a gain of RMB73.5 million in the same period of 2026. The improvement was primarily attributable to gains on disposal of a portion of our equity investment in an associated company, and the increase in foreign exchange gains in the first half of 2026.

Finance Income – Net

Net finance income decreased by about 60.3% to RMB19.9 million in the first half of 2026 from RMB50.1 million in the same period of 2025. The decrease was primarily due to the decrease in interest income from cash and cash equivalents.

Net Loss

Net loss increased by about 7.6% to RMB159.9 million in the first half of 2026 from RMB148.6 million in the same period of 2025.

Non-IFRS Measure

To supplement our consolidated financial statements, which are presented in accordance with IFRS, we also use adjusted net loss (non-IFRS measure) as an additional financial measure, which is not required by, or presented in accordance with IFRS. We believe this non-IFRS measure facilitates comparisons of operating performance from year to year and company to company by eliminating potential impacts of items, and provides useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as they help our management. However, our presentation of adjusted net loss (non-IFRS measure) may not be comparable to similarly titled measures presented by other companies. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for an analysis of, our results of operations or financial condition as reported under IFRS.

Excluding share-based compensation, the adjusted net loss (non-IFRS measure) was RMB122.7 million for the six months ended June 30, 2026, representing an increase of 7.3% from RMB114.4 million for the same period of 2025.

	For the six months ended June 30,	
	2026 (Unaudited) (RMB in thousands)	2025 (Unaudited) (RMB in thousands)
Reconciliation of net loss to adjusted net loss (non-IFRS measure):		
Net loss	**(159,947)**	(148,606)
Add:		
– Share-based compensation [1]	**37,237**	34,214
Adjusted net loss (non-IFRS measure)	**(122,710)**	(114,392)

Note:

(1) Share-based compensation is non-cash in nature and mainly represents the arrangement that we receive services from employees as consideration for our equity instruments. Share-based compensation is not expected to result in future cash payments.

LIQUIDITY AND CAPITAL RESOURCES

We monitor and maintain a level of liquidity deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows. As of June 30, 2026, we had RMB2,057.3 million in cash and cash equivalents, time deposits, restricted cash and restricted time deposits, as compared to RMB2,618.9 million as of December 31, 2025. Our cash and cash equivalents primarily consist of cash at banks under USD, RMB and HKD denominations.

Our net operating cash outflow in the first half of 2026 was RMB419.7 million, representing a decrease from RMB563.9 million in the same period of 2025. Our net cash used in operating activities in the first half of 2026 is calculated by adjusting our loss before income tax of RMB160.0 million by non-cash and other items to arrive at an operating loss before changes in working capital of RMB127.9 million.

INDEBTEDNESS AND FINANCIAL RATIOS

Borrowings

As of June 30, 2026, we had RMB525.4 million of bank borrowing.

Lease Liabilities

As of June 30, 2026, we recognized total lease liabilities, including current and non-current lease liabilities, of RMB144.2 million, as compared to that of RMB31.3 million as of December 31, 2025, due to the addition of the lease liabilities in the first half of 2026.

License Fees Payable

Our license rights are recognized as intangible assets. The license fees payable are initially recorded at fair value of the date of the license agreement. As of June 30, 2026, we recognized total license fees payables of RMB8.2 million, including current and non-current license fees payables, as compared to RMB12.7 million as of December 31, 2025, due to the fact that there was no new addition of license fees payables in the first half of 2026, and the decrease in balance was solely attributable to the payment of the license fees payables.

Financial Ratios

Our current ratio (calculated as current assets divided by current liabilities as of the same date) decreased to 310.9% as of June 30, 2026 from 384.3% as of December 31, 2025, mainly because of the increase in current liabilities.

Our gearing ratio (calculated as total liabilities divided by total assets as of the same date) increased to 32.6% as of June 30, 2026 from 27.7% as of December 31, 2025, mainly because of the increase in total liabilities.

CHARGE ON ASSETS

As of June 30, 2026, there was no charge on assets of our Group (June 30, 2025: nil).

CAPITAL EXPENDITURES AND CAPITAL COMMITMENTS

Our capital expenditures were primarily used for the construction of our manufacturing facilities. In the first half of 2026, our capital expenditures increased to RMB238.6 million from RMB39.0 million in the same period of 2025. In these periods, our capital expenditures were primarily used for construction of our manufacturing facilities and supply chain.

Our capital commitments were primarily related to (i) property, plant and equipment and (ii) intangible assets. As of June 30, 2026, we had capital commitments of RMB179.6 million, which was increased from our capital commitments of RMB113.3 million as of December 31, 2025. As of June 30, 2026, RMB175.6 million were attributable to property, plant and equipment and RMB4.0 million were attributable to intangible assets.

As disclosed in the Company's announcement dated March 5, 2025, we plan to use approximately 20% (or HK$197.8 million) of the net proceeds raised from the placing completed in February 2025 (the "**February 2025 Placing**") for establishing domestic and overseas production lines, enhancing the automation level of our production lines as well as devising stringent quality control measures at various stages of our manufacturing process, and approximately 10% (or HK$98.9 million) of the net proceeds raised from the February 2025 Placing for exploring potential strategic partnerships or alliance opportunities. See the abovementioned announcement for further details of our proposed use of proceeds from the February 2025 Placing. Save as disclosed in this interim report, the Group had no other material capital expenditure or investment plan as of the date of this interim report.

CONTINGENT LIABILITIES

As of June 30, 2026, we had a contingent liability in respect of several claims which were not practical to estimate the potential effect. See Note 22 to the interim condensed consolidated financial statements in this interim report for details.

SIGNIFICANT INVESTMENTS AND MATERIAL ACQUISITION AND DISPOSAL OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

Save as disclosed in this interim report, our Company had no other significant investments and/or material acquisition or disposal of subsidiaries, associates and joint ventures during the six months ended June 30, 2026.

HUMAN RESOURCES

As of June 30, 2026, we had over 2,200 employees and almost all of our employees were based in Mainland China. Our Group's total employee benefits for the Reporting Period were RMB452.7 million, consisting of wages, salaries and bonuses, share-based compensation expenses, severance payments, pension costs (including defined contribution plans, housing funds, medical insurances and other social insurances), and other employee benefits. We use various recruitment methods, including campus recruitment, online recruitment, other external recruitment channels as well as internal referrals and transfers. In addition to salaries and benefits, we generally provide performance-based bonuses for our full-time employees and commission for our sales and marketing staff. We have also established share incentive schemes, including the Pre-IPO Share Incentive Scheme A, the Pre-IPO Share Incentive Scheme B and the Post-IPO Share Incentive Scheme to incentivize our employees, details of which are set out in the Prospectus. We have established a comprehensive system for employee training and development, including general training covering corporate culture, employee rights and responsibilities, workplace safety, data security, and other logistics aspects, as well as specific trainings that improve employee knowledge and expertise in certain important areas related to our business. We are committed to making continued efforts to provide an engaging working environment to our employees.

During the Reporting Period, the Company made grants under the Post-IPO Share Incentive Scheme. On January 22, 2026, the Company granted restricted share units underlying a total of 583,874 Shares to eligible participants, who are the employees of the Group. On June 12, 2026, the Company granted (i) 470,000 share options to our executive Director and Chief Executive Officer (namely, Mr. Qiu Chunchao), and (ii) restricted share units underlying a total of 2,460,411 Shares to eligible participants, who are the employees of the Group. For details of these grants of awards under the Post-IPO Share Incentive Scheme, please refer to the Company's announcements dated January 22, 2026 and June 12, 2026.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

On January 5, 2024, the Shares of our Company were listed on the Main Board of the Stock Exchange. The net proceeds from the Global Offering (including the partial exercise of Over-allotment Option as disclosed in the announcement of the Company dated February 1, 2024) amounted to approximately HK$953.0 million. We plan to use the net proceeds raised from the Global Offering in the coming two to three years as follows:

- Approximately 45% of the net proceeds for our research and development to continue building and enhancing our product pipeline as well as team expansion for supporting our R&D initiatives;
- Approximately 20% of the net proceeds for enhancing our manufacturing, testing and verification capabilities;
- Approximately 20% of the net proceeds for enhancing our sales and marketing efforts;
- Approximately 5% of the net proceeds for exploring potential strategic partnerships or alliance opportunities; and
- Approximately 10% of the net proceeds for working capital and for general corporate purposes to support our business operation and growth.

For details of the proposed uses of proceeds from the Global Offering, see the section headed “Future Plans and Use of Proceeds” in the Prospectus. As of the Latest Practicable Date, we did not anticipate any material change to our plan on the use of proceeds as stated in the Prospectus.

As of June 30, 2026, we had utilized the net proceeds from the Global Offering as set out in the table below. We plan to use the unutilized amount of the net proceeds from the Global Offering for each intended use in the coming six months.

Intended use	Proportion of net proceeds allocated for each intended use (%)	Amount of net proceeds allocated for each intended use (HK$ million)	Amount of net proceeds utilized during the Reporting Period (HK$ million)	Amount of net proceeds utilized for each intended use as of June 30, 2026 (HK$ million)	Amount of net proceeds unutilized for each intended use as of June 30, 2026 (HK$ million)
For our research and development	45%	428.8	–	428.8	–
For enhancing our manufacturing, testing and verification capabilities	20%	190.6	–	190.6	–
For enhancing our sales and marketing efforts	20%	190.6	67.9	163.6	27.0
For exploring potential strategic partnerships or alliance opportunities	5%	47.7	–	47.7	–
For working capital and for general corporate purposes	10%	95.3	–	95.3	–

USES OF PROCEEDS FROM THE DECEMBER 2024 PLACING

On December 11, 2024 (before trading hours), the Company and China Renaissance Securities (Hong Kong) Limited (the "**Sole Placing Agent**") entered into a placing agreement, pursuant to which the Company agreed to appoint the Sole Placing Agent, and the Sole Placing Agent agreed to act as the agent of the Company, to procure not less than six (6) placees, who shall be institutional and corporate professional investors, and who and whose ultimate beneficial owners shall be the Independent Third Parties, on a best effort basis, to subscribe for up to 10,000,000 new Shares ("**placing shares**") (representing approximately 2.22% of the number of Shares in issue (excluding the Treasury Shares) as enlarged by the allotment and issuance of the placing shares in the December 2024 Placing) at the placing price of HK$27.75 per placing share (the "**December 2024 Placing**"). The placing price of HK$27.75 per placing share represents a discount of approximately 7.96% to the closing price of HK$30.15 per Share as quoted on the Stock Exchange on December 10, 2024 (being the last trading day immediately prior to the date of the placing agreement for the December 2024 Placing). The aggregate nominal value of the 10,000,000 placing shares was US$1,000. The December 2024 Placing was conducted under the general mandate granted to the Board at the annual general meeting dated June 27, 2024.

On December 18, 2024, the December 2024 Placing was completed. A total of 10,000,000 new Shares have been successfully placed by the Sole Placing Agent to not less than six (6) placees at the placing price of HK$27.75 per placing share in the December 2024 Placing. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the placees in the December 2024 Placing and its ultimate beneficial owners are institutional and corporate professional investors who are independent third parties. The total gross proceeds from the December 2024 Placing are approximately HK$277.5 million, and the net proceeds from the December 2024 Placing, after deducting the commission and other related expenses and professional fees, amounted to approximately HK$271.0 million. The net price per placing share in the December 2024 Placing was approximately HK$27.10.

As of June 30, 2026, we had utilized the net proceeds from the December 2024 Placing as set out in the table below. We plan to use the unutilized amount of the net proceeds from the December 2024 Placing for each intended use in the coming six months to one year.

Intended use	Proportion of net proceeds allocated for each intended use (%)	Amount of net proceeds allocated for each intended use (HK$ million)	Amount of net proceeds utilized during the Reporting Period (HK$ million	Amount of net proceeds utilized for each intended use as of June 30, 2026 (HK$ million)	Amount of net proceeds unutilized for each intended use as of June 30, 2026 (HK$ million)
For our research and development to continue enhancing the product pipelines as well as supporting the R&D initiatives in the areas of AI algorithms, chips and hardware	40%	108.4	–	108.4	–
For enhancing our business development efforts in the overseas markets	30%	81.3	–	–	81.3
For exploring potential strategic partnerships or alliance opportunities in the areas of AI algorithms, chips and hardware	20%	54.2	–	54.2	–
For working capital and for general corporate purposes	10%	27.1	–	27.1	–

For the reasons for and benefits of the December 2024 Placing and the details of the proposed uses of proceeds from the December 2024 Placing, see announcements of the Company dated December 11, 2024 and December 18, 2024 in relation to the December 2024 Placing. As of June 30, 2026, we did not anticipate any material change to our plan on the use of proceeds as stated in the abovementioned announcements.

USE OF PROCEEDS FROM THE FEBRUARY 2025 PLACING

On February 26, 2025 (before trading hours), the Company and Guotai Junan Securities (Hong Kong) Limited and Mirae Asset Securities (HK) Limited (the "**Placing Agents**") entered into a placing agreement, pursuant to which the Company agreed to appoint the Placing Agents, and the Placing Agents agreed to act as the agent of the Company, to procure not less than six (6) placees, who shall be institutional and corporate professional investors, and who and whose ultimate beneficial owners shall be the Independent Third Parties, on a best effort basis, to subscribe for up to 22,000,000 new Shares ("**placing shares**") (representing approximately 4.89% of the number of Shares in issue (excluding the Treasury Shares) as enlarged by the allotment and issuance of the placing shares in the December 2024 Placing) at the placing price of HK$46.15 per placing share (the "**February 2025 Placing**"). The placing price of HK$46.15 per placing share represents a discount of approximately 8.43% to the closing price of HK$50.40 per Share as quoted on the Stock Exchange on February 25, 2025 (being the last trading day and the date on which the placing price is fixed for the February 2025 Placing). The February 2025 Placing was conducted under the general mandate granted to the Board at the annual general meeting dated June 27, 2024.

On March 5, 2025, the February 2025 Placing was completed. A total of 22,000,000 new Shares have been successfully placed by the Placing Agents to not less than six (6) placees at the placing price of HK$46.15 per placing share in the February 2025 Placing. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the placees in the February 2025 Placing and its ultimate beneficial owners are institutional and corporate professional investors who are independent third parties. The total gross proceeds from the February 2025 Placing are approximately HK$1,015.30 million, and the net proceeds from the February 2025 Placing, after deducting the commission and other related expenses and professional fees, amounted to approximately HK$988.87 million. The net price per placing share in the February 2025 Placing was approximately HK$45.40.

As of June 30, 2026, we had utilized the net proceeds from the February 2025 Placing as set out in the table below. We plan to use the unutilized amount of the net proceeds from the February 2025 Placing for each intended use in the coming one to two years.

Intended use	Proportion of net proceeds allocated for each intended use (%)	Amount of net proceeds allocated for each intended use (HK$ million)	Amount of net proceeds utilized during the Reporting Period (HK$ million	Amount of net proceeds utilized for each intended use as of June 30, 2026 (HK$ million)	Amount of net proceeds unutilized for each intended use as of June 30, 2026 (HK$ million)
For our research and development of robotic incremental components	70%	692.2	137.6	137.6	554.6
For establishing domestic and overseas production lines, enhancing automation level of our production lines, and devising quality control measures	20%	197.8	54.8	156.1	41.7
For exploring strategic partnership or alliance opportunities	10%	98.9	34.3	63.6	35.3

For the reasons for and benefits of the February 2025 Placing and the details of the proposed uses of proceeds from the February 2025 Placing, see announcements of the Company dated February 26, 2025 and March 5, 2025 in relation to the February 2025 Placing. As of June 30, 2026, we did not anticipate any material change to our plan on the use of proceeds as stated in the abovementioned announcements.

TREASURY POLICY

Our management performs the treasury functions and continues to monitor our cash requirements from time to time. If our cash requirements exceed the liquidity we hold at the time, our Company may seek credit facilities and external borrowings or issue securities as it considers necessary and appropriate.

PRINCIPAL RISKS AND UNCERTAINTIES

Our business faces risks including those set out in the section headed “Risk Factors” in the Prospectus. The following list is a summary of certain principal risks and uncertainties facing the Group, some of which are beyond its control:

- We have a history of net losses, which may continue in the future;
- We have recorded net operating cash outflow in the past, which may reoccur in the future;
- The failure to innovate our technology or develop new products to adapt to changing customer needs could harm our growth;
- Continued pricing pressures from our customers, many of whom possess significant bargaining power, may result in lower than anticipated revenue and margins, which may materially and adversely affect our business prospects and results of operations;
- We are susceptible to supply shortages, long lead times and increased costs of raw materials and key components, any of which could disrupt our supply chain, increase our production costs, adversely affect our profitability and delay deliveries of our products to customers;
- As the LiDAR and robotics industry in which we operate is new and rapidly evolving, we are subject to intense competition and it is difficult to forecast adoption rates and demand for our products. If market adoption of LiDAR and/or robotics products does not continue to grow according to expectations, it could materially and adversely affect our business prospects and results of operations;
- There is no guarantee that our automotive OEM customers will purchase our products and solutions in any certain quantity or at any certain price even after we obtain design wins, and the period of time from product design to mass production is long and we are subject to the risks of termination or postponement of contracts or unsuccessful implementation; and
- Changes in China’s or global economic, political or social conditions or government policies, including, without limitation, geopolitical tensions, tensions in international trades, imposition of or increase in any industry-specific or product-specific tariffs, investigations, designations or outbound investment restrictions on or against Chinese companies engaged in certain activities involving specified sensitive technologies, or export control measures, may have a material and adverse impact on our business operation, financial performance or position, or prospects.

RISK MANAGEMENT

We are exposed to a variety of financial risks, including market risks (including foreign currency risk and interest rate risk), credit risk and liquidity risk as set out below. Our overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on our financial performance. Risk management is carried out by the senior management of our Group. Our management regularly manages and monitors the financial risks of our Group to ensure appropriate measures are implemented in a timely and effective manner. During the Reporting Period, no hedging activity was undertaken by our Group.

Market Risk

Foreign Exchange Risk

Foreign exchange risk is the risk that the value of a financial instrument fluctuates because of the changes in foreign exchange rates. Foreign exchange risk arises when future commercial transactions or recognized assets and liabilities are denominated in a currency that is not the respective functional currency of our Group's entities. The functional currency of our Company and the majority of its overseas subsidiaries is USD whereas the functional currency of the PRC subsidiaries is RMB. Our Group is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to RMB, USD and HKD.

During the Reporting Period, our Group did not hedge transactions undertaken in foreign currencies but managed its foreign exchange risk by performing regular reviews of our Group's net foreign exchange exposures. See Note 5(a) to the interim condensed consolidated financial statements in this interim report for details.

Interest Rate Risk

Our Group's interest rate risk primarily arises from time deposits and cash and cash equivalents. Those carried at floating rates expose our Group to cash flow interest rate risk whereas those carried at fixed rates expose our Group to fair value interest rate risk. Our Group regularly monitors the interest rate risk to ensure there is no undue exposure to significant interest rate movements.

During the Reporting Period, our Group did not have any significant interest-bearing liabilities nor any significant interest-bearing assets except for cash and cash equivalents, time deposits, restricted cash, restricted time deposits, financial assets at amortize cost and borrowings. The fair value interest rate risk arises from financial assets and liabilities carried at fixed rates was not significant for our Group during the Reporting Period. See Note 5(a) to the interim condensed consolidated financial statements in this interim report for details.

Credit Risk

Our Group is exposed to credit risk in relation to its cash and cash equivalents, time deposits, restricted cash, trade and notes receivables, other receivables and financial assets at FVOCI. The carrying amounts of above items represent our Group's maximum exposure to credit risk in relation to financial assets. The management of our Group manages credit risk on a group basis.

As of June 30, 2026, our cash and cash equivalent were mainly placed with reputable financial institutions in the PRC and Hong Kong without significant credit issue, and our Group was not exposed to significant credit risk arising from other receivables having considered the counterparties' past operational and financial performance and other factors. See Note 5(a) to the interim condensed consolidated financial statements in this interim report for details.

Liquidity Risk

Liquidity risk is the risk that our Group is unable to meet its obligations when they fall due, resulting from amount and maturity mismatches of assets and liabilities. Prudent liquidity risk management implies maintaining sufficient cash and cash equivalents and the availability of funding. Due to the nature of the underlying businesses, our management responsible for treasury function aims to maintain flexibility in funding by keeping sufficient cash available. See Note 5(a) to the interim condensed consolidated financial statements in this interim report for details.

OTHER INFORMATION

INTERIM DIVIDEND

The Board did not recommend the distribution of any interim dividend for the six months ended June 30, 2026 (six month ended June 30, 2025: Nil).

EVENTS AFTER THE REPORTING PERIOD

As disclosed in the Company's announcement dated September 10, 2026 (the "**Announcement**"), Shenzhen Suteng (an indirect wholly-owned subsidiary of the Company) and Shenzhen Xiyuan Robotics Co., Ltd. ("**Shenzhen Xiyuan**") entered into a transfer agreement, pursuant to which Shenzhen Suteng agreed to sell, and Shenzhen Xiyuan agreed to purchase, certain Target Business and Asset (as defined in the Announcement) at a total cash consideration of RMB59,878,000 ("**Proposed Disposal**"). The Proposed Disposal constitutes a connected transaction of the Company under Chapter 14A of the Listing Rules. For details of the Proposed Disposal, please refer to the Announcement.

Save as disclosed above and in Note 23 to the interim condensed consolidated financial statements set forth in this interim report, we are not aware of any material subsequent events since the end of the Reporting Period to the date of this interim report.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES OR SALE OF TREASURY SHARES

During the Reporting Period, the Company repurchased a total of 215,000 Shares on the Stock Exchange at an aggregate consideration of approximately HK$5.0 million (excluding transaction fees).

Subsequent to the Reporting Period and up to the Latest Practicable Date, the Company repurchased a total of 1,104,700 Shares on the Stock Exchange at an aggregate consideration of approximately HK$18.5 million (excluding transaction fees).

As of Latest Practicable Date, 13,587,900 Shares repurchased had not been cancelled and were held by the Company as Treasury Shares. Subsequent to the Reporting Period and as of the Latest Practicable Date, the Company had no present intention to use or sell the Treasury Shares.

Save as disclosed above, during the Reporting Period and up to the Latest Practicable Date, neither the Company nor its subsidiaries had purchased, sold or redeemed any of the listed securities of the Company.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of its Shareholders. The principles of the Company's corporate governance are to promote effective internal control measures, to enhance transparency of the work of the Board, and to strengthen accountability to all the Shareholders.

The Corporate Governance Code set out in Part 2 of Appendix C1 to the Listing Rules has become applicable to our Company with effect from the Listing Date. During the Reporting Period, the Company has complied with the applicable code provisions under the Corporate Governance Code set out in Part 2 of Appendix C1 to the Listing Rules.

DIRECTORS' SECURITIES TRANSACTIONS

The Board has adopted the Model Code as the code of conduct regulating Directors' dealings in securities of the Company. In response to specific enquiries made by the Board, all Directors confirmed that they have complied with the provisions of the Model Code during the Reporting Period.

REVIEW OF INTERIM RESULTS AND INTERIM REPORT

The Board has established the Audit Committee which comprises two independent non-executive Directors, namely Mr. Ng Yuk Keung and Mr. Liu Ming, and one non-executive Director, namely Dr. Zhu Xiaorui. Mr. Ng Yuk Keung is the chairman of the Audit Committee. The primary duties of the Audit Committee are to review the financial controls and the internal control and risk management systems of our Group, monitor the integrity of the Company's financial statements, review and monitor the external auditor's independence and objectivity and effectiveness of the audit process and perform other duties and responsibilities as assigned by our Board.

The Audit Committee has reviewed the unaudited interim condensed consolidated financial statements of the Group for the Reporting Period.

The independent auditor of the Company, PricewaterhouseCoopers, has also reviewed the interim condensed consolidated financial statements of the Group for the Reporting Period in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the International Auditing and Assurance Standards Board.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

Save as disclosed in this interim report, the Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

CHANGES OF DIRECTORS' INFORMATION

Save as disclosed in this interim report, as at the date of this interim report, there were no changes in the Directors' information which are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS OR SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As of June 30, 2026, the interests or short positions of the Directors or the chief executives of the Company in the Shares, underlying Shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which had been notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have taken under such provisions of the SFO), or which were recorded in the register required to be kept pursuant to section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

Interests in the Shares or Underlying Shares of the Company

Name of Director	Nature of Interest	Number of Interested Shares [2]	Approximate Percentage of Shareholding Interest [1]
Dr. Qiu Chunxin ("**Dr. Qiu**")	Interests held jointly with another person [3]	97,082,430 (L)	20.04%
	Interests held jointly with another person [3]	7,300,000 (S)	1.51%
Dr. Zhu Xiaorui ("**Dr. Zhu**")	Interests held jointly with another person [3]	97,082,430 (L)	20.04%
	Interests held jointly with another person [3]	7,300,000 (S)	1.51%
Mr. Liu Letian ("**Mr. Liu**")	Interests held jointly with another person [3]	97,082,430 (L)	20.04%
	Interests held jointly with another person [3]	7,300,000 (S)	1.51%
Mr. Qiu Chunchao	Beneficiary of a trust (other than a discretionary interest)	9,107,746 (L)	1.88%

1. The number of issued Shares as of June 30, 2026 was 484,468,553 (including Treasury Shares).

2. The letter "L" stands for long position, and the letter "S" stands for short position.

3. Each of Dr. Qiu, Dr. Zhu and Mr. Liu (collectively as the "**Founders**") entered into the concert party confirmation dated April 21, 2023 to formalize and confirm that they have been parties acting in concert in exercising directors and shareholders' rights of our Group since the Founders become shareholders or directors of the relevant member of the Group (whichever is earlier). As such, each of Dr. Qiu, Dr. Zhu and Mr. Liu is deemed to be interested in the Shares held by other members of the Founders for the purpose of Part XV of the SFO.

Save as disclosed above, as of June 30, 2026, none of the Directors or the chief executives of the Company had or was deemed to have any interest or short position in the Shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) that was required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or required to be recorded in the register required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

Substantial Shareholders' Interests and/or Short Position in Shares and Underlying Shares of the Company

As of June 30, 2026, so far as was known to the Directors, the following persons/entities (other than the Directors or chief executive of the Company) had, or were deemed to have, interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO were as follows:

Name of Substantial Shareholder	Nature of Interest	Number of Interested Shares [2]	Approximate Percentage of Shareholding Interest [1]
BlackPearl Global Limited ("**BlackPearl**") [3]	Beneficial owner	49,367,683 (L)	10.19%
BlackPearl Investment Limited [3]	Interest of controlled corporation	49,367,683 (L)	10.19%
Sunton Global Limited ("**Sunton Global**") [3]	Beneficiary of a trust (other than a discretionary interest)	49,367,683 (L)	10.19%
Dr. Qiu [3, 6]	Interests held jointly with another person	97,082,430 (L)	20.04%
	Interests held jointly with another person	7,300,000 (S)	1.51%
Emerald Forest International Limited ("**Emerald Forest**") [4]	Beneficial owner	29,604,176 (L)	6.11%
	Beneficial owner	7,300,000 (S)	1.51%
Emerald Forest Investment Limited [4]	Interest of controlled corporation	29,604,176 (L)	6.11%
	Interest of controlled corporation	7,300,000 (S)	1.51%
Emerald Forest Holding Limited ("**Emerald Forest Holding**") [4]	Beneficiary of a trust (other than a discretionary interest)	29,604,176 (L)	6.11%
	Beneficiary of a trust (other than a discretionary interest)	7,300,000 (S)	1.51%
Dr. Zhu [4, 6]	Interests held jointly with another person	97,082,430 (L)	20.04%
	Interests held jointly with another person	7,300,000 (S)	1.51%
Mr. Liu [6]	Interests held jointly with another person	97,082,430 (L)	20.04%
	Interests held jointly with another person	7,300,000 (S)	1.51%
TMF (Cayman) Ltd. [3, 4, 5]	Trustee	101,931,831 (L)	21.04%
	Trustee	7,300,000 (S)	1.51%

1. The number of issued Shares as of June 30, 2026 was 484,468,553 (including Treasury Shares).

2. The letter "L" stands for long position, and the letter "S" stands for short position.

3. BlackPearl is owned as to 99.9% by BlackPearl Investment Limited and 0.1% by Sunton Global. Sunton Global is wholly owned by Dr. Qiu. BlackPearl Investment Limited is held by TMF (Cayman) Ltd. acting as trustee of a trust, with Sunton Global and Dr. Qiu as beneficiaries. As such, each of Dr. Qiu, BlackPearl Investment Limited, Sunton Global and TMF (Cayman) Ltd. is deemed to be interested in the Shares held by BlackPearl for the purpose of Part XV of the SFO.

4. Emerald Forest is owned as to 99.9% by Emerald Forest Investment Limited and 0.1% by Emerald Forest Holding. Emerald Forest Holding is wholly owned by Dr. Zhu. Emerald Forest Investment Limited is held by TMF (Cayman) Ltd. acting as trustee of a trust, with Emerald Forest Holding and Dr. Zhu as beneficiaries. As such, each of Dr. Zhu, Emerald Forest Investment Limited, Emerald Forest Holding and TMF (Cayman) Ltd. is deemed to be interested in the Shares held by Emerald Forest for the purpose of Part XV of the SFO.

5. One of the ESOP Holding Entities, Ruby International Limited ("**Ruby**"), holding 4,849,401 Shares underlying the awards in the form of restricted shares granted to Mr. Qiu pursuant to pre-IPO share incentive scheme adopted by the Company on December 30, 2021 (the "**Pre-IPO Share Incentive Scheme A**"), is owned as to 99.9% by Ruby Group Holdings Limited and 0.1% by Sunton Limited, which is in turn wholly owned by Mr. Qiu. Ruby Group Holdings Limited is held by TMF (Cayman) Ltd. as the trustee of a trust, with Sunton Limited and Mr. Qiu as the beneficiaries. As such, TMF (Cayman) Ltd. is deemed to be interested in the Shares held by Ruby for the purpose of Part XV of the SFO.

6. Each of Dr. Qiu, Dr. Zhu and Mr. Liu entered into the concert party confirmation to formalize and confirm that they have been parties acting in concert in exercising directors and shareholders' rights of our Group since the Founders become shareholders or directors of the relevant member of the Group (whichever is earlier). As such, each of Dr. Qiu, Dr. Zhu and Mr. Liu is deemed to be interested in the Shares held by other members of the Founders for the purpose of Part XV of the SFO.

Save as disclosed above, as of June 30, 2026, the Directors were not aware of any other persons/entities (other than the Directors and chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

POST-IPO SHARE INCENTIVE SCHEME

The following is a summary of the principal terms of the share incentive scheme conditionally adopted and approved by our Shareholders with effect from June 29, 2023 (the "**Post-IPO Share Incentive Scheme**"). The Post-IPO Share Incentive Scheme is effective from the date of approval by the Shareholders (the "**Effective Date**"). The Post-IPO Share Incentive Scheme remains in force for a period of 10 years after the Effective Date.

(a) Purposes

The purposes of the Post-IPO Share Incentive Scheme are (i) to promote the success and enhance the value of the Company by aligning the personal interests of the directors of members of the Group and the employees to those of the Shareholders and motivating their outstanding performance to promote the Group's development and generate returns to the Shareholders; and (ii) to provide flexibility to the Company in its ability to motivate, attract, and retain the services of directors of members of the Group and the employees upon whose judgment, interest, and special effort the successful conduct of the Company's operation is largely dependent.

(b) **Types of awards**

The Post-IPO Share Incentive Scheme provides for an award of (i) a right to purchase a specified number of Shares at a specified price during specified time periods (the "**Option**" or "**Share Options**"), (ii) a Share that is subject to certain restrictions and may be subject to risk of forfeiture (the "**Restricted Share**") or (iii) a right to receive a Share at a future date (the "**Restricted Share Unit**") (collectively, the "**Awards**").

(c) **Participants**

Persons eligible to participate in the Post-IPO Share Incentive Scheme (the "**Participants**") include: (i) any person, including an officer or member of the Board of any member of the Group, who is in the employ of any member of the Group, subject to the control and direction of any member of the Group as to both the work to be performed and the manner and method of performance (the "**Employees**"); and (ii) all directors of any member of the Group, as determined by the Board or a committee delegated by the Board pursuant to the Post-IPO Share Incentive Scheme.

(d) **Maximum number of Shares**

The maximum aggregate number of Shares which may be issued pursuant to all Awards (including Options) is 21,000,000 Shares (the "**Scheme Mandate Limit**"), representing approximately 4.33% of the Shares in issue as of the Latest Practicable Date.

(e) **Maximum entitlement of each Participant**

Where any grant of awards or options to a Participant would result in the total number of Shares issued and to be issued in respect of all awards or options granted (excluding any options and awards lapsed in accordance with the terms of the Post-IPO Share Incentive Scheme or any other share schemes of the Company) under the Post-IPO Share Incentive Scheme and any other share schemes of the Company in the 12-month period up to and including the date of such grant representing in aggregate over 1% of the total number of Shares in issue, such grant must be separately approved by the Shareholders in general meeting in accordance with the requirements of the Listing Rules with such Participant and his/her close associate (or associates), if the Participant is a connected person (as defined under the Listing Rules), or such persons as may be required under the Listing Rules from time to time, abstaining from voting. The number and terms of Options to be granted to such Participant must be fixed before the approval of the Shareholders. In such event, the Company must send a circular to the Shareholders containing all information required under the Listing Rules.

(f) Performance target

The Board has the right to implement specific provisions (such as provisions on performance assessment) to determine whether or not unvested Awards can vest in favor of the Participants according to schedule or whether or not vested but unexercised Awards can be exercised by the Participants.

(g) Exercise price of an Option

The exercise price of an Option shall be determined by the Board and set forth in the written agreement, contract, or other instrument or document evidencing an Award, including through electronic medium, entered into between the Company and a Participant and any amendment thereto (the "**Award Agreement**").

The exercise price of an Option may be a fixed or variable price related to the fair market value of the Share provided that such exercise price shall be at least the higher of (1) the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the date of grant, which must be a business day; and (2) a price being the average of the closing prices of the Shares as stated in the Stock Exchange's daily quotations sheets for the five (5) trading days immediately preceding the date of grant.

Notwithstanding the above, the exercise price per Share may be adjusted or amended in the absolute discretion of the Board to the extent permitted by the applicable laws (including the Listing Rules), the determination of which shall be final, binding and conclusive.

(h) Vesting schedule

Vesting period for Options

The Board may specify the exercise period and/or vesting schedule for Options granted in the Award Agreement, which may be based on performance criteria, passage of time or other factors of any combination thereof, provided that an Option must be held by the Participant for at least 12 months before the Option can be exercised, save for a shorter exercise period may be granted to the Participant in any of the following circumstances below at the sole discretion of the Board:

i. grants of "make-whole" Options to new Employees to replace the share options or share awards they forfeited when leaving his or her previous employer;

ii. grants to a Participant whose employment is terminated due to death or disability or occurrence of any out of control event;

iii. grants that are made in batches during a year for administrative and compliance reasons;

iv. grants with a mixed or accelerated vesting schedule such as where the Option may vest evenly over a period of 12 months;

v. grants with performance-based vesting conditions in lieu of time-based vesting criteria; or

vi. grants of Options with a total vesting and holding period of more than 12 months.

Vesting period for Restricted Shares and/or Restricted Share Units

The Board may specify the vesting schedule for Restricted Shares and/or Restricted Share Units granted in the Award Agreement, which may be based on performance criteria, passage of time or other factors of any combination thereof, provided that the vesting period for Restricted Shares and/or Restricted Share Units shall not be less than 12 months, save for a shorter vesting period may be granted to the Participant in any of the following circumstances at the sole discretion of the Board:

i. grants of "make-whole" Restricted Shares and/or Restricted Share Units to new Employees to replace the share options or share awards they forfeited when leaving his or her previous employer;

ii. grants to a Participant whose employment is terminated due to death or disability or occurrence of any out of control event;

iii. grants that are made in batches during a year for administrative and compliance reasons;

iv. grants with a mixed or accelerated vesting schedule such as where the Restricted Shares and/or Restricted Share Units may vest evenly over a period of 12 months;

v. grants with performance-based vesting conditions in lieu of time-based vesting criteria; or

vi. grants of Restricted Shares and/or Restricted Share Units with a total vesting and holding period of more than 12 months.

(i) Non-transferability of the Awards

Any Awards granted shall be personal to the Participant, and no right or interest of a Participant in any Award may be pledged, encumbered, or hypothecated to or in favor of any party other than the Company or a subsidiary, or shall be subject to any lien, obligation, or liability of such Participant to any other party other than the Company or a subsidiary. Except as otherwise provided by the Board, no Award shall be assigned, transferred, or otherwise disposed of by a Participant.

(j) Grant to Connected Persons

Any grant of Awards to a connected person (as defined in the Listing Rules) of the Company or any of his or her associates (as defined in the Listing Rules) shall comply with and shall be approved in accordance with the applicable requirements under the Listing Rules.

(k) Expiration of Options, Restricted Shares and/or Restricted Share Units

(i) An Option may not be exercised and (ii) a Restricted Share or a Restricted Share Unit may not be vested and will automatically lapse upon the occurrence of any one of the following events:

(1) the earlier of ten years from the date it is granted and listing of the Shares on a recognized stock exchange, unless an earlier time is set in the Award Agreement;

(2) upon the Participant's termination of employment or retirement as an Employee or cessation, retirement or vacation of directorship as a director of any member of the Group (as the case may be);

(3) upon the Participant's disability or death, subject to other requirements as provided under the Post-IPO Share Incentive Scheme; and

(4) upon the Participant being convicted of any criminal offense involving his or her integrity or honesty, or charged, convicted or held liable for any offense under the relevant securities laws, regulations or rules in force from time to time in Hong Kong or elsewhere.

(l) Amendment, Modification and Termination

At any time and from time to time, the Board may terminate, amend or modify the Post-IPO Share Incentive Scheme; provided, however, that (a) to the extent necessary and desirable to comply with applicable laws, or stock exchange rules, the Company shall obtain shareholder approval of any amendment of the Post-IPO Share Incentive Scheme in such a manner and to such a degree as required, and (b) shareholder approval is required for any amendment to the Post-IPO Share Incentive Scheme that (i) increases the number of Shares available under the Post-IPO Share Incentive Scheme (other than any adjustment as provided under the Post-IPO Share Incentive Scheme) to the extent permitted under the applicable laws, (ii) permits the Board to extend the term of the Post-IPO Share Incentive Scheme or the exercise period for an Option beyond ten years from the date of grant to the extent permitted under the applicable laws, (iii) results in a material increase in benefits or a change in eligibility requirements, (iv) is of material nature to the advantage of the Participants, or (v) changes the authority of the Board to alter the terms of the Post-IPO Share Incentive Scheme.

Details of Grants of Awards during the Reporting Period

The number of Shares available for Awards under the Post-IPO Share Incentive Scheme as of January 1, 2026 was 9,978,769 Shares.

During the Reporting Period, the Company made grants under the Post-IPO Share Incentive Scheme. On January 22, 2026, the Company granted RSUs underlying a total of 583,874 Shares to eligible participants, who are the employees of the Group. On June 12, 2026, the Company granted (i) 470,000 Options to our executive Director and Chief Executive Officer (namely, Mr. Qiu Chunchao), and (ii) RSUs underlying a total of 2,460,411 Shares to eligible participants, who are the employees of the Group. For details of these grants of awards under the Post-IPO Share Incentive Scheme, please refer to the Company's announcements dated January 22, 2026 and June 12, 2026.

Save as disclosed above, none of the above grantees involved in these grants falls within any category described in Rule 17.06A(2) of the Listing Rules, namely (a) the Director, chief executive or substantial shareholder of the Company, or an associate of any of them; (b) a participant of whom the total number of options and awards granted and to be granted thereto exceeds the 1% individual limit as prescribed under Rule 17.03D of the Listing Rules; or (c) a related entity participant or service provider participant of whom the total number of options and awards granted and to be granted thereto in any 12-month period exceeds 0.1% of the relevant class of Shares in issue (excluding Treasury Shares).

Movement of the awarded RSUs and/or Options during the Reporting Period are set out as follows:

Category of grantees	Date of grant	Types of Awards	Closing price immediately before the date of grant (HKD per Share)	Purchase price/exercise price of Awards (HKD per Share)	Number of Shares underlying the Awards granted	Number of Awards that are not exercised or vested as of January 1, 2026	Vested during the Reporting Period	Cancelled during the Reporting Period	Lapsed/ forfeited during the Reporting Period [1]	Number of Awards that are not exercised or vested as of June 30, 2026	Vesting period/ exercise period [2]
Employees	July 5, 2024	RSUs	HK$50.95	Nil	216,607	–	–	–	–	–	12 months after the date of grant
Employees	April 1, 2025	RSUs	HK$38.15	Nil	1,312,523	832,388	248,740	–	48,995	534,653	One month to 49 months after the date of grant
Employees	June 4, 2025	Options	HK$32.05	HK$33.87	8,800,000	8,750,000	–	–	250,000	8,500,000	In two batches in 2028 and 2029
Employees	July 18, 2025	RSUs	HK$33.50	Nil	1,181,397	554,492	95,165	–	35,377	423,950	One month to 48 months
Employees	January 22, 2026	RSUs	HK$38.58	Nil	583,874	–	796	–	105,501	477,587	Six months to 48 months after the date of grant
Director	June 12, 2026	Options	HK$28.80	HK$30.46	470,000	–	–	–	–	470,000	In two batches between December 25, 2028 an January 31, 2030
Employees	June 12, 2026	RSUs	HK$28.80	Nil	2,460,411	–	–	–	–	2,460,411	Ten months to 49 months after the date of grant

Notes:

(1) Pursuant to the terms of the Post-IPO Share Incentive Scheme and in accordance with note 1 to Rule 17.03B of the Listing Rules, if any Awards are forfeited or lapsed, such Shares may again be optioned, granted or awarded under the Post-IPO Share Incentive Scheme.

(2) The vesting period/exercise period of the grants refers to (in the case of RSUs) the period from the date of grant to the date of vesting or (in the case of Share Options) the period from the date of grant to the date of vesting upon which the Share Options can be exercised.

(3) The weighted average closing price of the Shares immediately before the dates on which the Awards were vested was approximately HK$33.85 per Share.

(4) The number of Shares that may be issued in respect of Awards granted under all schemes of the Company during the Reporting Period divided by the weighted average number of Shares of the relevant class in issue (excluding Treasury Shares) for the Reporting Period was approximately 3.18%.

(5) The accounting standard and policy adopted with respect to the awards granted during the Reporting Period are set out as follows. Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration all non-market vesting conditions is expensed on a straight-line basis over the vesting period, based on the Group's estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share award scheme reserve). At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest based on assessment of all relevant non-market vesting conditions. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the share award scheme reserve. When share awards are exercised, the amount previously recognized in share award scheme reserve will be transferred to share capital and share premium. When the shares awards are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognized in share award scheme reserve will be transferred to accumulated losses.

Save for the grants of the RSUs and Options as disclosed above, no Award has been granted, exercised, cancelled, lapsed or remained outstanding under the Post-IPO Share Incentive Scheme during the six months ended June 30, 2026.

Details of Grant of Awards after the Reporting Period

After the Reporting Period, on September 16, 2026, the Company granted RSUs underlying a total of 1,616,341 Shares to eligible participants, who are the employees of the Group. The Shares underlying the RSUs shall vest within a period approximately between seven months and 43 months after the date of grant pursuant to the vesting schedule specified in the award agreement. For details of the above grant of awards, please refer to the Company's announcement dated September 16, 2026.

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

羅兵咸永道

To the Board of Directors of RoboSense Technology Co., Ltd
(incorporated in the Cayman Islands with limited liability)

Introduction

We have reviewed the interim financial information set out on pages 44 to 77, which comprises the interim condensed consolidated balance sheet of RoboSense Technology Co., Ltd (the "**Company**") and its subsidiaries (together, the "**Group**") as of June 30, 2026 and the interim condensed consolidated statements of comprehensive income for the three months and six months periods then ended, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six months period then ended, and selected explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting". The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PricewaterhouseCoopers
22/F Prince's Building, Central
Hong Kong SAR, China
T: +852 2289 8888, F: +852 2810 9888

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 “Interim Financial Reporting”.

PricewaterhouseCoopers
Certified Public Accountants
Hong Kong, August 26, 2026

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

		Three months ended June 30,		Six months ended June 30,	
		2026	2025	2026	2025
		RMB'000	RMB'000	RMB'000	RMB'000
	Notes	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Revenue	6	**560,999**	455,365	**1,019,749**	783,207
Cost of sales		**(438,411)**	(329,239)	**(797,560)**	(580,071)
Gross profit		**122,588**	126,126	**222,189**	203,136
Research and development expenses		**(183,706)**	(163,837)	**(346,452)**	(308,712)
Sales and marketing expenses		**(37,841)**	(28,759)	**(73,827)**	(56,894)
General and administrative expenses		**(51,578)**	(37,729)	**(93,686)**	(78,317)
Net (losses)/reversal of impairment losses on financial assets		**(874)**	783	**848**	4,066
Other income		**35,082**	25,350	**45,691**	39,789
Other gains/(losses) – net	7	**21,146**	1,952	**73,463**	(217)
Operating loss		**(95,183)**	(76,114)	**(171,774)**	(197,149)
Finance income		**10,715**	29,867	**26,657**	54,037
Finance costs		**(3,923)**	(2,053)	**(6,780)**	(3,929)
Finance income – net		**6,792**	27,814	**19,877**	50,108
Share of net (loss)/profit of associates accounted for using the equity method		**(7,764)**	398	**(8,085)**	621
Loss before income tax		**(96,155)**	(47,902)	**(159,982)**	(146,420)
Income tax (expenses)/benefits	8	**(469)**	(1,918)	**35**	(2,186)
Net loss		**(96,624)**	(49,820)	**(159,947)**	(148,606)
(Loss)/profit attributable to:					
Owners of the Company		**(96,995)**	(51,387)	**(161,219)**	(150,980)
Non-controlling interests		**371**	1,567	**1,272**	2,374
		(96,624)	(49,820)	**(159,947)**	(148,606)

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Notes	Three months ended June 30, 2026 RMB'000 (Unaudited)	Three months ended June 30, 2025 RMB'000 (Unaudited)	Six months ended June 30, 2026 RMB'000 (Unaudited)	Six months ended June 30, 2025 RMB'000 (Unaudited)
Other comprehensive loss					
Items that may be reclassified to profit or loss					
Currency translation differences		**536**	(844)	**1,467**	(1,150)
Items that will not be reclassified to profit or loss					
Currency translation differences		**(64,124)**	(11,134)	**(128,902)**	(15,181)
Other comprehensive loss, net of tax		**(63,588)**	(11,978)	**(127,435)**	(16,331)
Total comprehensive loss		**(160,212)**	(61,798)	**(287,382)**	(164,937)
Total comprehensive (loss)/ income attributable to:					
Owners of the Company		**(160,583)**	(63,365)	**(288,654)**	(167,311)
Non-controlling interests		**371**	1,567	**1,272**	2,374
		(160,212)	(61,798)	**(287,382)**	(164,937)
Loss per share for loss attributable to the owners of the Company:					
Basic and diluted (expressed in RMB per share)	9	**(0.21)**	(0.11)	**(0.35)**	(0.33)

The above interim condensed consolidated statements of comprehensive income should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

	Notes	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
ASSETS			
Non-current assets			
Property, plant and equipment	10	**464,908**	292,729
Right-of-use assets		**135,748**	28,869
Intangible assets		**33,635**	37,014
Investments accounted for using the equity method	11	**55,725**	34,984
Financial assets at fair value through profit or loss	14	**191,918**	170,540
Time deposit		**20,358**	20,183
Other non-current assets		**88,058**	43,483
		990,350	627,802
Current assets			
Inventories	12	**539,671**	395,171
Trade and notes receivables	13	**658,234**	800,267
Prepayments, other receivables and other current assets		**315,105**	211,147
Financial assets at fair value through other comprehensive income		**15,838**	18,141
Financial assets at fair value through profit or loss	14	**149,689**	224,509
Financial assets at amortized cost		**442,855**	369,735
Restricted time deposit		**–**	24,612
Time deposits		**1,109,063**	341,744
Restricted cash		**7,980**	154,681
Cash and cash equivalents		**940,300**	2,097,873
Current assets excluding assets classified as held for sale		**4,178,735**	4,637,880
Assets classified as held for sale	15	**104,848**	–
		4,283,583	4,637,880
Total assets		**5,273,933**	5,265,682
EQUITY			
Share capital	16(a)	**336**	336
Other reserves	16(b)	**13,365,802**	13,458,507
Accumulated losses	16(b)	**(9,831,439)**	(9,670,220)
Capital and reserves attributable to owners of the Company		**3,534,699**	3,788,623
Non-controlling interests		**18,088**	16,816
Total equity		**3,552,787**	3,805,439

	Notes	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
LIABILITIES			
Non-current liabilities			
Borrowings	18	**154,400**	157,300
Lease liabilities		**113,550**	18,975
Government grants		**23,511**	26,631
Deferred tax liabilities		**12,066**	14,308
Other non-current liabilities		**39,907**	36,106
		343,434	253,320
Current liabilities			
Trade payables	19	**485,329**	545,673
Contract liabilities		**25,779**	20,535
Borrowings	18	**370,951**	289,917
Lease liabilities		**30,628**	12,350
Other payables and accruals		**409,341**	338,448
Total current liabilities excluding liabilities relating to assets held for sale		**1,322,028**	1,206,923
Liabilities relating to assets classified as held for sale	15	**55,684**	–
		1,377,712	1,206,923
Total liabilities		**1,721,146**	1,460,243
Total equity and liabilities		**5,273,933**	5,265,682

The above interim condensed consolidated balance sheet should be read in conjunction with the accompanying notes.

The interim condensed consolidated financial information on pages 44 to 77 were approved by the Board of Directors on August 26, 2026 and were signed on its behalf.

Dr. Qiu Chunxin
Chairman of the Board and Executive Director

Mr. Qiu Chunchao
Executive Director and Chief Executive Officer

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

		Attributable to owners of the Company					
	Notes	Share capital RMB'000	Other reserves RMB'000	Accumulated losses RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
		(Note 16(a))	*(Note 16(b))*	*(Note 16(b))*			
(Unaudited)							
As of January 1, 2026		336	13,458,507	(9,670,220)	3,788,623	16,816	3,805,439
Net (loss)/profit		–	–	(161,219)	(161,219)	1,272	(159,947)
Other comprehensive loss, net of tax:							
– currency translation differences		–	(127,435)	–	(127,435)	–	(127,435)
Total comprehensive (loss)/income		–	(127,435)	(161,219)	(288,654)	1,272	(287,382)
Transactions with owners in their capacity as owners:							
Repurchase of ordinary shares		–	(4,342)	–	(4,342)	–	(4,342)
Employee share scheme:							
– value of employee services	16(b)	–	37,237	–	37,237	–	37,237
– vesting of restricted share units ("**RSUs**")	16(b)	–	1,835	–	1,835	–	1,835
Total transactions with owners in their capacity as owners		–	34,730	–	34,730	–	34,730
As of June 30, 2026		336	13,365,802	(9,831,439)	3,534,699	18,088	3,552,787

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

		Attributable to owners of the Company					
		Share capital	Other reserves	Accumulated losses	Total	Non-controlling interests	Total equity
	Notes	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		(Note 16(a))	*(Note 16(b))*	*(Note 16(b))*			
(Unaudited)							
As of January 1, 2025		319	12,581,298	(9,524,298)	3,057,319	15,860	3,073,179
Net (loss)/profit		–	–	(150,980)	(150,980)	2,374	(148,606)
Other comprehensive loss, net of tax:							
– currency translation differences		–	(16,331)	–	(16,331)	–	(16,331)
Total comprehensive (loss)/income		–	(16,331)	(150,980)	(167,311)	2,374	(164,937)
Transactions with owners in their capacity as owners:							
Issuance of ordinary shares relating to placing, net of underwriting commissions and other issuance costs	16(b)	16	912,193	–	912,209	–	912,209
Issuance of ordinary shares relating to RSUs	16(b)	1	(1)	–	–	–	–
Repurchase of ordinary shares		–	(16,630)	–	(16,630)	–	(16,630)
Employee share scheme:							
– value of employee services	16(b)	–	34,214	–	34,214	–	34,214
– vesting of RSUs	16(b)	–	1,835	–	1,835	–	1,835
Total transactions with owners in their capacity as owners		17	931,611	–	931,628	–	931,628
As of June 30, 2025		336	13,496,578	(9,675,278)	3,821,636	18,234	3,839,870

The above interim condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	Six months ended June 30,	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Cash flows from operating activities		
Cash used in operations	**(435,253)**	(613,921)
Interest received	**26,657**	54,037
Interest paid	**(6,759)**	(4,047)
Income taxes paid	**(4,299)**	–
Net cash used in operating activities	**(419,654)**	(563,931)
Cash flows from investing activities		
Purchase of property, plant and equipment	**(156,424)**	(24,917)
Proceeds from disposal of property, plant and equipment	**816**	496
Receipt of government grants related to assets	**2,019**	14,690
Purchase of intangible assets	**(2,044)**	(2,576)
Receipt of premium from derivative financial instruments	**637**	7,270
Payment for settlement of derivative financial instruments	**–**	(1,235)
Purchase of financial assets at fair value through profit or loss	**(379,812)**	(378,029)
Proceeds from disposal of financial assets at fair value through profit or loss	**410,393**	243,559
Proceeds from disposal of investment in an associate measured at fair value through profit or loss	**50,000**	–
Purchase of financial assets at amortised cost	**(619,950)**	(143,172)
Proceeds from disposal of financial assets at amortised cost	**537,589**	–
Purchase of restricted time deposit and time deposits	**(1,112,331)**	(71,483)
Proceeds from maturity of time deposits and restricted time deposit	**358,970**	–
Deposit of restricted cash	**(3,205)**	(50,110)
Refund of restricted cash	**142,054**	28,634
Loans advanced to a third party	**(3,000)**	–
Interest received from time deposits, restricted time deposit and financial assets at amortized cost	**10,725**	243
Payment for investment in an associate	**(29,531)**	–
Net cash used in investing activities	**(793,094)**	(376,630)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	Six months ended June 30,	
	2026	**2025**
	RMB'000	**RMB'000**
	(Unaudited)	**(Unaudited)**
Cash flows from financing activities		
Proceeds from bank borrowings	**277,448**	160,000
Repayment of bank borrowings	**(116,000)**	(1,100)
Repurchase of ordinary shares	**(4,342)**	(16,630)
Principal elements of lease payments	**(6,204)**	(6,365)
Principal elements of license fees payable	**(3,988)**	(5,394)
Proceeds from issuance of ordinary shares relating to placing	**–**	913,111
Payments for placing expenses	**–**	(1,485)
Net cash generated from financing activities	**146,914**	1,042,137
Net (decrease)/increase in cash and cash equivalents	**(1,065,834)**	101,576
Cash and cash equivalents at the beginning of the period	**2,097,873**	2,835,984
Effects of exchange rate changes on cash and cash equivalents	**(51,896)**	(16,263)
Cash and cash equivalents at the end of the period	**980,143**	2,921,297
Included in cash and cash equivalents per the balance sheet	**940,300**	2,921,297
Included in the assets classified as held for sales	**39,843**	–

The above interim condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1 General information

RoboSense Technology Co., Ltd (the "**Company**") and its subsidiaries (together, the "**Group**") are principally engaged in (i) developing and producing LiDAR products for applications in advanced driver assistance systems ("**ADAS**"), as well as robotics and others, (ii) LiDAR perception solutions, combining LiDAR hardware and AI perception software, and (iii) services in the People's Republic of China (the "**PRC**").

The Company is an investment holding company and was incorporated in the Cayman Islands on June 23, 2021 as an exempted company with limited liability. The address of the Company's registered office is the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

Suteng Innovation Technology Co., Ltd. ("**Shenzhen Suteng**"), an indirect wholly owned subsidiary of the Company, was incorporated in the PRC in August 2014. The business of the Group was mainly carried out by Shenzhen Suteng and its subsidiaries.

On April 21, 2023, Dr. Qiu Chunxin, Dr. Zhu Xiaorui and Mr. Liu Letian (collectively the "**Founders**") entered into the Concert Party Confirmation, to formalize and confirm that they have been parties acting in concert in exercising directors and shareholders' rights of the Group and aligning their votes in the board and shareholders' meetings of the Group since the Founders become shareholders or directors of the relevant member of the Group (whichever is earlier).

The Company's shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited since January 5, 2024.

This interim condensed consolidated financial information comprises the interim condensed consolidated balance sheet of the Group as of June 30, 2026, the interim condensed consolidated statements of comprehensive income for the three months and six months periods then ended, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six months period then ended, and selected explanatory notes (the "**Interim Financial Information**").

This Interim Financial Information is presented in Renminbi ("**RMB**"), unless otherwise stated. This Interim Financial Information has been approved for issue by the board of directors on August 26, 2026.

This Interim Financial Information has not been audited but has been reviewed by the independent auditor of the Company.

2 Basis of preparation

The Interim Financial Information has been prepared in accordance with International Accounting Standard ("**IAS**") 34, "Interim Financial Reporting". The Interim Financial Information should be read in conjunction with the annual consolidated financial statements of the Group for the year ended December 31, 2025 as set out in the annual report of the Company, which have been prepared in accordance with International Financial Reporting Accounting Standards ("**IFRS**") and disclosure requirement of the Hong Kong Companies Ordinance Cap. 622 ("**HKCO**").

3 Material accounting policy information

The accounting policies applied in the preparation of the Interim Financial Information are consistent with those of the annual financial statements of the Company for the year ended December 31, 2025, except for the adoption of new and amended IFRS Accounting Standards effective for the financial period beginning on January 1, 2026.

(a) New and amended standards adopted by the Group

The following amendments to standards have been adopted by the Group for the financial period beginning on January 1, 2026:

Amendments	Subject of Amendments
Amendments to IFRS 9 and IFRS 7	Classification and Measurement of Financial Instruments
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Annual improvements to IFRS – Volume 11	Annual improvements

The adoption of the above amendments does not have a material impact on the results and financial position of the Group.

3 Material accounting policy information (Continued)

(b) New and amended standards and interpretations not yet adopted by the Group

Certain amendments to standards have been issued but are not yet effective and have not been early adopted by the Group during the period. The Group has already commenced an assessment of the impact of these new and amended standards and has concluded on a preliminary basis that adoption of these new and amended standards is not expected to have significant impacts on the financial performance and positions of the Group when they become effective, except for IFRS 18, which will mainly impact the presentation of consolidated financial statements.

Amendments	Subject of amendments	Effective for accounting periods beginning on or after
IFRS 18	Presentation and Disclosure in Financial Statements	January 1, 2027
IFRS 19 and Amendments	Subsidiaries without Public Accountability: Disclosures	January 1, 2027
Amendments to IAS 21	Translation to a Hyperinflationary Presentation Currency	January 1, 2027
Amendments to IFRS 10 and IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined
Amendments to IAS 28	Fair value option for investments in associates and joint ventures	January 1, 2027
IFRS 20	Regulatory Assets and Regulatory Liabilities	January 1, 2029

4 Critical accounting estimates and judgments

The preparation of Interim Financial Information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

As disclosed in Note 4 to the consolidated financial statements in 2025 annual report, provision for product warranties are recognized based on sales volume and past experience of the level and returns. In the six months ended June 30, 2026, the Group, based on management's best estimate, has made an additional provision of RMB18,702,500 for customers' claim. The result may be subject to changes, given the uncertainty in the estimation.

Except for above change in preparing the Interim Financial Information, the significant judgments made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the annual report.

5 Financial risk management

(a) Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, interest rate risk and price risk), credit risk and liquidity risk. The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group's financial performance. Risk management is carried out by the senior management of the Group.

The Group's policies on financial risk management were set out in the annual report and there have been no significant changes in the financial risk management policies for the six months ended June 30, 2026.

5 Financial risk management (Continued)

(b) Fair value estimation

The Group analyzes its financial instruments' fair value by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorized into three levels within a fair value hierarchy as follows:

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
- Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
- Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

The following table presents the Group's assets and liabilities that are measured at fair value.

	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
As of June 30, 2026 (Unaudited)				
Assets				
Financial assets at fair value through profit or loss ("**FVTPL**")	**13,154**	**–**	**328,453**	**341,607**
Financial assets at fair value through other comprehensive income ("**FVOCI**")	**–**	**–**	**15,838**	**15,838**
	13,154	**–**	**344,291**	**357,445**
As of December 31, 2025 (Audited)				
Assets				
Financial assets at FVTPL	24,819	129,012	241,218	395,049
Financial assets at FVOCI	–	–	18,141	18,141
	24,819	129,012	259,359	413,190

5 Financial risk management (Continued)

(b) Fair value estimation (Continued)

(i) The following table presents the changes in level 3 items of financial assets at FVOCI, financial assets at FVTPL and derivative financial instruments for the six months ended June 30, 2026 and 2025.

	Six months ended June 30,	
	2026	**2025**
	RMB'000	**RMB'000**
	(Unaudited)	**(Unaudited)**
Assets		
Financial assets at FVOCI		
At the beginning of the period	**18,141**	23,254
Additions	**167,359**	90,196
Disposals	**(169,662)**	(97,742)
At the end of the period	**15,838**	15,708
Financial assets at FVTPL		
At the beginning of the period	**241,218**	34,197
Additions	**139,812**	342,181
Change in fair value	**9,108**	1,969
Disposals	**(57,543)**	(243,559)
Foreign currency translation adjustments	**(4,142)**	–
At the end of the period	**328,453**	134,788
Liabilities		
Derivative financial instruments		
At the beginning of the period	**–**	–
Additions	**–**	7,270
Change in fair value	**637**	(4,068)
Disposals	**(637)**	(1,235)
At the end of the period	**–**	1,967
Net unrealized gains recognized in profit or loss for the period attributable to balances held at the end of the reporting period – Financial assets at FVTPL	**8,548**	371

5 Financial risk management (Continued)

(b) Fair value estimation (Continued)

(ii) Valuation techniques used to determine fair values

The Group has a team that manages the valuation of level 3 instruments for financial reporting purposes. The team manages the valuation exercise of the investments on a case-by-case basis. External valuation experts will be involved when necessary.

The valuation of the level 3 instruments mainly included financial assets at FVOCI and financial assets at FVTPL (Note 14). As these instruments are not traded in an active market, their fair values have been determined by using various applicable valuation techniques, including:

- For the valuation of notes receivables measured at FVOCI and investments with a variable interest rate indexed to the performance of underlying assets accounted for financial assets measured at FVTPL, discounted cash flow model is used and unobservable inputs are involved, mainly including assumptions of expected future cash flows and discount rate; and

- For the valuation of debt investments and equity investments in ordinary shares with special rights in an associate and unlisted companies measured at FVTPL, the market approach is adopted, with reference to the prices of recent transactions in equity instruments of the same investee, and the resulting equity value is allocated among the different classes of equity of the investee based on their respective rights and preferences under a range of possible exit scenarios. The significant unobservable inputs mainly include assumptions of scenarios probabilities and expected volatility.

There was no change to valuation techniques for the six months ended June 30, 2026 and 2025.

The management assessed the sensitivity from the unobservable inputs for the change of fair value of financial assets at FVOCI and financial assets at FVTPL for the six months ended June 30, 2026 and 2025 and the result was immaterial.

There was no transfer between level 1, 2 and 3 of fair value hierarchy classification for the six months ended June 30, 2026.

6 Revenue and segment information

(a) Segment information

The Group's business activities, for which discrete financial statements are available, are regularly reviewed and evaluated by the chief operating decision-maker ("**CODM**") who is the Chief Executive Officer of the Company. As a result of this evaluation, the CODM considers that the Group's operations are operated and managed as a single segment. Accordingly, no segment information is presented.

The Company is domiciled in the Cayman Islands while the Group mainly operates its businesses in the PRC and earns the revenue from customers in the PRC and other geographic locations as follows:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	RMB'000	RMB'000	RMB'000	RMB'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Revenue from:				
PRC	**492,267**	413,802	**917,886**	717,577
Others	**68,732**	41,563	**101,863**	65,630
	560,999	455,365	**1,019,749**	783,207

As of June 30, 2026 and December 31, 2025, substantially all of the non-current assets of the Group were located in the PRC.

(b) Disaggregation of revenue

The breakdown of revenue for the three and six months ended June 30, 2026 and 2025 is as follows:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	RMB'000	RMB'000	RMB'000	RMB'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Revenue from:				
Products	**516,880**	418,736	**958,003**	721,026
Solutions	**7,256**	29,629	**17,220**	51,174
Services and others	**36,863**	7,000	**44,526**	11,007
	560,999	455,365	**1,019,749**	783,207

(i) The Group's revenue was recognized at a point in time for the three and six months ended June 30, 2026 and 2025.

7 Other gains/(losses) – net

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	RMB'000	RMB'000	RMB'000	RMB'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Foreign exchange gains/(losses), net	**21,090**	2,234	**41,287**	(737)
Realized gains from disposal of investment in an associate measured at FVTPL (Note 14)	**–**	–	**28,146**	–
Net fair value gains on financial assets and liabilities at FVTPL (Note 14)	**108**	237	**4,391**	909
Net losses on disposal of property, plant and equipment	**(32)**	(341)	**(251)**	(523)
Others	**(20)**	(178)	**(110)**	134
	21,146	1,952	**73,463**	(217)

8 Income tax (expenses)/benefits

The income tax (expenses)/benefits of the Group for the three and six months ended June 30, 2026 and 2025 are analysed as below:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	RMB'000	RMB'000	RMB'000	RMB'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Current income tax expenses	**(469)**	(1,918)	**(2,207)**	(2,186)
Deferred income tax benefits	**–**	–	**2,242**	–
	(469)	(1,918)	**35**	(2,186)

Income tax (expenses)/benefits are recognised based on management's best estimate of the weighted average annual income tax rate expected for the full financial year.

9 Loss per share

(a) Basic loss per share

Basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the period.

In determining the weighted average number of ordinary shares in issue, the unvested restricted shares and share options are excluded:

	Three months ended June 30,		Six months ended June 30,	
	2026	**2025**	**2026**	**2025**
	RMB'000	**RMB'000**	**RMB'000**	**RMB'000**
	(Unaudited)	**(Unaudited)**	**(Unaudited)**	**(Unaudited)**
Loss attributable to the owners of the Company (RMB'000)	**(96,995)**	(51,387)	**(161,219)**	(150,980)
Weighted average number of ordinary shares outstanding	**466,844,008**	464,853,332	**466,671,179**	457,206,245
Basic loss per share (in RMB)	**(0.21)**	(0.11)	**(0.35)**	(0.33)

(b) Diluted loss per share

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. For the three and six months ended June 30, 2026 and 2025, the Company had one category of potential ordinary shares: share-based awards granted to employees. As the Company incurred losses for the three and six months ended June 30, 2026 and 2025, these potential ordinary shares were not included in the calculation of loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the three and six months ended June 30, 2026 and 2025 are the same as basic loss per share.

10 Property, plant and equipment

	Machinery and equipment RMB'000	Mold and tooling RMB'000	Computer, electronic equipment and others RMB'000	Vehicles RMB'000	Leasehold improvements RMB'000	Construction in progress RMB'000	Total RMB'000
At January 1, 2026							
Cost	219,625	36,140	56,990	10,662	104,904	82,937	511,258
Accumulated depreciation	(76,961)	(29,068)	(34,996)	(6,273)	(71,231)	–	(218,529)
Net book amount	142,664	7,072	21,994	4,389	33,673	82,937	292,729
Six months ended June 30, 2026 (Unaudited)							
Opening net book amount	142,664	7,072	21,994	4,389	33,673	82,937	292,729
Additions	738	34	72	–	19,646	214,313	234,803
Disposals	(652)	(260)	(69)	(86)	–	–	(1,067)
Transfers	49,872	6,006	16,941	168	6,912	(79,899)	–
Transfer to assets classified as held for sale (Note 15)	(510)	–	(102)	–	(15,710)	(9,913)	(26,235)
Foreign currency translation adjustments	(4)	–	(3)	(11)	(100)	(65)	(183)
Depreciation charge	(17,663)	(3,559)	(4,929)	(1,183)	(7,805)	–	(35,139)
Closing net book amount	174,445	9,293	33,904	3,277	36,616	207,373	464,908
At June 30, 2026 (Unaudited)							
Cost	268,114	40,742	73,733	10,649	113,294	207,373	713,905
Accumulated depreciation	(93,669)	(31,449)	(39,829)	(7,372)	(76,678)	–	(248,997)
Net book amount	174,445	9,293	33,904	3,277	36,616	207,373	464,908

10 Property, plant and equipment (Continued)

	Machinery and equipment RMB'000	Mold and tooling RMB'000	Computer, electronic equipment and others RMB'000	Vehicles RMB'000	Leasehold improvements RMB'000	Construction in progress RMB'000	Total RMB'000
At January 1, 2025							
Cost	175,644	29,377	102,426	11,164	81,782	55,659	456,052
Accumulated depreciation	(51,021)	(19,872)	(42,719)	(4,557)	(66,323)	–	(184,492)
Net book amount	124,623	9,505	59,707	6,607	15,459	55,659	271,560
Six months ended June 30, 2025 (Unaudited)							
Opening net book amount	124,623	9,505	59,707	6,607	15,459	55,659	271,560
Additions	–	–	5	–	4,966	28,830	33,801
Disposals	(357)	(198)	(27)	(435)	–	–	(1,017)
Transfers	8,645	4,833	3,683	879	6,512	(24,552)	–
Foreign currency translation adjustments	–	53	(51)	18	–	–	20
Depreciation charge	(13,753)	(6,535)	(11,548)	(1,355)	(3,591)	–	(36,782)
Closing net book amount	119,158	7,658	51,769	5,714	23,346	59,937	267,582
At June 30, 2025 (Unaudited)							
Cost	182,795	32,547	106,024	11,626	92,172	59,937	485,101
Accumulated depreciation	(63,637)	(24,889)	(54,255)	(5,912)	(68,826)	–	(217,519)
Net book amount	119,158	7,658	51,769	5,714	23,346	59,937	267,582

11 Investments accounted for using the equity method

In April 2026, the Group acquired 30% ordinary equity interest in a private company for a consideration of USD4,373,624 (approximately RMB30 million). The Group holds one of three board seats in the investee to enable it to participate in the investee's financial and operating activities. As a result, the investee is recognised as an associate of the Group and accounted for using the equity method.

12 Inventories

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Raw materials (Note (a))	**214,128**	149,472
Work-in-progress (Note (a))	**241,305**	128,347
Finished goods (Note (b))	**152,521**	155,269
Fulfillment cost	**5,435**	5,381
	613,389	438,469
Less: provision for inventories (Note (c))	**(73,718)**	(43,298)
– Raw materials (Note (c))	**(16,961)**	(16,380)
– Work-in-progress (Note (c))	**(27,158)**	(3,819)
– Finished goods (Note (c))	**(29,599)**	(23,099)
	539,671	395,171

(a) Raw materials and work-in-progress primarily consist of materials mainly for volume production as well as materials used for trial production.

(b) Finished goods primarily consist of products that are ready for sale at production factories or in transit to fulfil customer orders.

(c) Provision for inventories is recognized for the amount by which the carrying amount of the inventories exceeds the net recoverable amount, and is recorded in cost of sales in the interim condensed consolidated statement of comprehensive income. The provision for inventories recognized for six months ended June 30, 2026 amounted to RMB50,250,000 (2025: RMB9,151,000).

(d) The cost of inventories recognized as cost of sales for six months ended June 30, 2026 amounted to RMB683,563,000 (2025: RMB551,841,000).

(e) As of June 30, 2026 and December 31, 2025, no inventories were pledged as collaterals.

13 Trade and notes receivables

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Trade receivables (Note (a))	**494,417**	616,919
Notes receivables (Note (b))	**182,408**	202,968
	676,825	819,887
Less: credit loss allowances	**(18,591)**	(19,620)
	658,234	800,267

(a) As of June 30, 2026 and December 31, 2025, the ageing analysis of the trade receivables based on recognition date is as follows:

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Up to 6 months	**450,305**	582,364
6 months to 1 year	**25,242**	16,940
1 to 2 years	**6,744**	6,347
Over 2 years	**12,126**	11,268
	494,417	616,919
Less: credit loss allowances	**(18,591)**	(19,620)
Trade receivables – net	**475,826**	597,299

(b) The maturity dates of notes receivables are normally within 6 months.

The Group's trade and notes receivables are mainly denominated in RMB and their carrying amounts approximated their fair value.

The Group applies the simplified approach to provide for expected credit losses prescribed by IFRS 9.

14 Financial assets at fair value through profit or loss

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Non-current assets		
Investment in an associate measured at FVTPL (Note (a))	**145,224**	131,122
Investments in unlisted companies (Note (b))	**46,694**	39,418
	191,918	170,540
Current assets		
Investment in listed equity securities (Note (c))	**13,154**	24,819
Investment in wealth management products (Note (d))	**136,535**	199,690
	149,689	224,509
Total financial assets at FVTPL	**341,607**	395,049

(a) In July 2025, the Group made an investment amounting to RMB35,738,000 in ordinary shares of a private company with special rights, including liquidation preference right, redemption right and anti-dilution protection right, under certain circumstances. The Group also holds board seat in the investee to enable it can participate in the investee' financial and operating activities. As a result, the investee is an associate of the Group. Considering the impact of the special rights, the Group accounts for the investment in the associate as financial assets at FVTPL.

In January 2026, the Group and a third-party investor entered into a share subscription agreement with the associate to acquire 3.5% and 1.5% equity interest of the associate for a consideration of RMB35,000,000 and RMB15,000,000, respectively. On the same day, the Group entered into a share transfer agreement with another third party to transfer 5% of the Group's equity interest in the associate for a total cash consideration of RMB50,000,000. The difference between the cash consideration and the carrying value of the 5% equity interest being transferred out amounting to RMB28,146,000 was recognized in other gains/(losses) – net for the six months ended June 30, 2026 (2025: N/A).

14 Financial assets at fair value through profit or loss (Continued)

(a) (Continued)

In determining the fair value of the investment as of June 30, 2026, the Group considered the financing event of the associate that was completed in January 2026 disclosed above. The Group assessed that this financing event was an arm's length transaction between the associate and independent third-party investors. The Group assessed that there were no significant events or changes in circumstances between the financing date and June 30, 2026 that would have a material impact on the fair value of the investment.

The transaction price implied by the financing event was used as the basis for estimating the total equity value of the associate, which was then allocated among the various classes of equity securities using the Black-Scholes option pricing model, taking into account the rights and preferences attaching to each class, including liquidation preferences, redemption rights and anti-dilution provisions. The fair value gain of the remaining equity interest in the associate held by the Group was RMB956,000 for the six months ended June 30, 2026 (2025: N/A).

As of June 30, 2026, the Group holds 28.5% equity interest in the associate with special rights, and the investment is accounted for as financial assets at FVTPL.

(b) The Group invested in ordinary shares with special rights (referred to as "**preferred shares**") in unlisted companies. These investments held by the Company contain certain embedded derivatives. Following an assessment of the Group's business model for managing financial assets and a test of whether the contractual cash flows represent solely payments of principal and interest ("**SPPI**"), the Group recognized these investments at FVTPL. The Group assesses the fair value of these financial assets on a periodic basis. Management applies appropriate valuation techniques to determine their respective fair values. For the six months ended June 30, 2026, a fair value gain of RMB7,276,000 was recognized in other gains/(losses) – net (2025: Nil).

(c) The Group disposed of a portion of the investment in a listed equity security. The realized disposal gain of RMB460,000 was recognized in other gains/(losses) – net for the six months ended June 30, 2026 (2025: N/A). The unrealized fair value loss of RMB6,262,000 was recognized in other gains/(losses) – net for the six months ended June 30, 2026 (2025: losses RMB5,128,000).

(d) The net fair value gains of RMB1,961,000 on investment in wealth management products measured at FVTPL for the six months ended June 30, 2026 was recognized in other gains/(losses) – net (2025: gains RMB6,037,000).

15 Assets and liabilities classified as held for sale

In June 2026, the management of the Company committed to a plan to sell its sub-group in Singapore at its current condition and concluded that it is not likely that there will be significant changes made to the plan or that the plan will be withdrawn as of June 30, 2026. The management has initiated an active program to locate a buyer and the sale is highly probable to be completed within one year.

The associated assets and liabilities ("**disposal group**") were consequently classified as held for sale as of June 30, 2026.

	As of June 30, 2026 RMB'000 (Unaudited)
Assets classified as held for sale	
– Property, plant and equipment	**26,235**
– Trade and notes receivables	**14,466**
– Right-of-use assets	**9,884**
– Other non-current assets	**5,805**
– Inventories	**5,095**
– Prepayments, other receivables and other current assets	**1,316**
– Restricted cash	**2,204**
– Cash and cash equivalents	**39,843**
Total assets classified as held for sale	**104,848**
Liabilities relating to assets classified as held for sale	
– Contract liabilities	**37,699**
– Lease Liabilities	**10,944**
– Other payables and accruals	**7,041**
Total liabilities relating to assets classified as held for sale	**55,684**

The cumulative foreign exchange gains recognised in other comprehensive income in relation to the disposal group classified as held for sale as of June 30, 2026 were RMB167,000.

16 Share capital and reserves

(a) Share capital

	Number of ordinary shares	Equivalent nominal value of ordinary share USD'000	Share capital RMB'000
Issued:			
As of January 1, 2026 and June 30, 2026	**484,468,553**	**48**	**336**
As of January 1, 2025	460,939,423	46	319
Issuance relating to placing (Note (a)(i))	22,000,000	2	16
Issuance relating to RSUs (Note (a)(ii))	1,529,130	–	1
As of June 30, 2025	484,468,553	48	336

(i) On March 5, 2025, the Company successfully completed the placing of 22,000,000 shares at HKD46.15 per placing share to not less than six placees. The total gross proceeds from the placing are approximately RMB936.6 million and the net proceeds after deducting the underwriting commissions and other issuance costs are approximately RMB912.2 million.

(ii) On April 30, 2025, the Company issued 1,529,130 new ordinary shares with a par value of US$0.0001 each relating to RSUs granted under a post-IPO share incentive scheme.

16 Share capital and reserves (Continued)

(b) Reserves movement of the Group

	Note	Treasury shares RMB'000 (i)	Share premium RMB'000	Capital reserve RMB'000	Share-based compensation reserve RMB'000	Foreign currency translation reserve RMB'000	Subtotal RMB'000	Accumulated losses RMB'000	Total RMB'000
(Unaudited)									
As of January 1, 2026		(185,822)	14,050,685	(67,112)	105,104	(444,348)	13,458,507	(9,670,220)	3,788,287
Loss for the period		-	-	-	-	-	-	(161,219)	(161,219)
Currency translation differences		-	-	-	-	(127,435)	(127,435)	-	(127,435)
Repurchase of ordinary shares	(i)	(4,342)	-	-	-	-	(4,342)	-	(4,342)
Employee share scheme:									
– value of employee services		-	-	-	37,237	-	37,237	-	37,237
– vesting of RSUs		1	34,683	-	(32,849)	-	1,835	-	1,835
As of June 30, 2026		(190,163)	14,085,368	(67,112)	109,492	(571,783)	13,365,802	(9,831,439)	3,534,363

(i) During the six months ended June 30, 2026, the Company repurchased 215,000 of its own shares from the market. The shares were repurchased at prices ranging from HKD22.88 to HKD23.00 per share, with an average price of HKD22.99 per share. The total consideration of approximately RMB4,342,000 paid, including the transaction costs of the equity transaction, is deducted from equity attributable to owners of the Company as treasury shares.

As of June 30, 2026, 12,483,200 repurchased ordinary shares were included in treasury shares.

As of June 30, 2026, 5,231,503 ordinary shares were issued related to RSUs and included in treasury shares.

16 Share capital and reserves (Continued)

(b) Reserves movement of the Group (Continued)

	Note	Treasury shares RMB'000 (ii)	Share premium RMB'000	Capital reserve RMB'000	Share-based compensation reserve RMB'000	Foreign currency translation reserve RMB'000	Subtotal RMB'000	Accumulated losses RMB'000	Total RMB'000
(Unaudited)									
As of January 1, 2025		(150,956)	13,063,809	(67,112)	86,511	(350,954)	12,581,298	(9,524,298)	3,057,000
Loss for the period		–	–	–	–	–	–	(150,980)	(150,980)
Currency translation differences		–	–	–	–	(16,331)	(16,331)	–	(16,331)
Issuance of ordinary shares relating to placing, net of underwriting commissions and other issuance costs		–	912,193	–	–	–	912,193	–	912,193
Issuance of ordinary shares relating to RSUs		–	(1)	–	–	–	(1)	–	(1)
Repurchase of ordinary shares	(ii)	(16,630)	–	–	–	–	(16,630)	–	(16,630)
Employee share scheme:									
– value of employee services		–	–	–	34,214	–	34,214	–	34,214
– vesting of RSUs		1	39,495	–	(37,661)	–	1,835	–	1,835
As of June 30, 2025		(167,585)	14,015,496	(67,112)	83,064	(367,285)	13,496,578	(9,675,278)	3,821,300

(ii) During the six months ended June 30, 2025, the Company repurchased 617,000 of its own shares from the market. The shares were repurchased at prices ranging from HKD26.65 to HKD29.00 per share, with an average price of HKD27.97 per share. The total consideration of approximately RMB16,630,000 paid, including the transaction costs of the equity transaction, is deducted from equity attributable to owners of the Company as treasury shares.

As of June 30, 2025, 11,655,200 repurchased ordinary shares were included in treasury shares.

As of June 30, 2025, 7,924,054 ordinary shares were issued related to RSUs and included in treasury shares.

17 Dividends

No dividends have been paid or declared by the Company during the six months ended June 30, 2026 (2025: Nil).

18 Borrowings

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Included in non-current liabilities		
– Non-current portion of long-term bank borrowings, unsecured (Note (a))	**154,400**	157,300
Included in current liabilities		
– Bank borrowings, unsecured (Note (a))	**215,105**	29,105
– Current portion of long-term bank borrowings, unsecured (Note (a))	**84,900**	234,000
– Collateralized borrowing (Note (b))	**70,946**	26,812
	370,951	289,917
	525,351	447,217

(a) As of June 30, 2026, the Group's unsecured bank borrowings were denominated in RMB with an effective interest rate of 2.1% to 2.7% per annum (December 31, 2025: 2.2% to 3.1% per annum).

(b) The Company has entered into notes receivable discounting arrangements with several banks. As the Company retains substantially all risks and rewards associated with the notes, the transaction is accounted for as a collateralized borrowing. The carrying amount of notes receivable pledged as collateral for this borrowing was RMB70,946,000 as of June 30, 2026 (December 31, 2025: RMB26,812,000). As of June 30, 2026, the secured borrowing is carried at amortized cost and bears interest ranged from 0.5% to 1.4% (December 31, 2025: from 0.8% to 1.8%), repayable within 6 months.

(c) As of June 30, 2026 and December 31, 2025, the carrying amounts of borrowings approximated their fair values.

19 Trade payables

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Trade payables	**485,329**	545,673

The carrying amounts of trade payables approximate as their fair value due to their short-term maturity in nature.

As of June 30, 2026 and December 31, 2025, the ageing analysis of the trade payables based on the date of the goods and services received are as follows:

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Up to 6 months	**483,966**	540,189
Between 6 months and 1 year	**971**	3,861
Over 1 year	**392**	1,623
	485,329	545,673

20 Related party transactions

The following is a summary of the transactions carried out between the Group and its related parties during the six months ended June 30, 2026 and 2025, and balances with related parties as of June 30, 2026 and December 31, 2025.

(a) Name and relationship with related parties

The following individuals/companies are related parties of the Group that had significant balances and/or transactions with the Group as of June 30, 2026 and December 31, 2025 or during the six months ended June 30, 2026 and 2025.

Name of related parties	Relationship with the Group
Company A	Associate of the Group
Company B	Associate of the Group
Company C	Associate of the Group
Company D	Associate of the Group
Mr. Qiu Chunchao	Executive Director and Chief Executive Officer
Dr. Qiu Chunxin	Founding shareholder
Mr. Liu Letian	Founding shareholder
Dr. Zhu Xiaorui	Founding shareholder

(b) Significant transactions and balances with related parties

The following transactions occurred with associates:

	Six months ended June 30,	
	2026	**2025**
	RMB'000	**RMB'000**
	(Unaudited)	**(Unaudited)**
Purchase of goods and services	**27,643**	150,879
Purchase of property, plant and equipment	**20,498**	3,043
Sales of goods, services and others	**99**	–

20 Related party transactions (Continued)

(b) Significant transactions and balances with related parties (Continued)

	Six months ended June 30, 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Loans to associates		
Beginning of the year	**50,274**	–
Interest charged	**485**	–
End of year	**50,759**	–

The following balances are outstanding at the end of the reporting period in relation to transactions with associates:

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Trade payables	**20,423**	76,680
Other payables	**12,788**	1,884
Other receivables	**4,176**	4,176
Contract liabilities	**15**	59
Trade receivables	**–**	98

20 Related party transactions (Continued)

(c) Key management compensation

Key management includes directors and senior managements. The compensation paid or payable to key management for employee services is shown below:

	Six months ended June 30, 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Wages, salaries and bonuses	**2,928**	2,925
Share-based compensation expenses	**1,347**	2,638
Pension costs – defined contribution plans, housing funds, medical insurances and other social insurances	**173**	166
	4,448	5,729

21 Commitments

Significant capital expenditure and investment contracted for at the end of the reporting period but not recognized as liabilities are as follows:

	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
Contracted but not provided for		
– Property, plant and equipment	**175,630**	108,331
– Investment commitment	**13,622**	–
– Intangible assets	**3,952**	4,976
	193,204	113,307

22 Contingencies

(a) Contingent assets

The subsidiary of the Group, Shenzhen Suteng has lodged claims against a company ("**the Defendant**") in 2025, for misappropriation of trade secrets and infringement of patents, and seeking total damages of RMB91,000,000. In 2026, Shenzhen Suteng filed additional claims against the Defendant in relation to invention patent infringement, breach of contract, invention patent ownership dispute and unfair competition via commercial defamation, with the total claimed damages amounting to RMB11,300,000. As of June 30, 2026, all claims have been formally accepted and registered by the court, and three of them have been at the trial stage in August 2026.

The directors concluded that the outcomes of these litigations remained uncertain at this stage. As of June 30, 2026, the Group's contingent assets were not recognised as receivables, as receipt of the amount was dependent on the outcome of the litigation process.

(b) Contingent liabilities

The Group has a contingent liability in respect of a claim for RMB20,500,000, which was lodged against Shenzhen Suteng by the aforementioned Defendant in 2025 in relation to alleged infringement of a certain patent right, and was dismissed by the court in June 2026 for the patent being entirely invalid. In 2026, the aforementioned Defendant filed additional claims against Shenzhen Suteng for alleged misappropriation of trade secrets, infringement of other patent rights and commercial defamation, claiming total damages of RMB102,300,000, which includes RMB20,300,000 relating to a claim that was subsequently withdrawn by the Defendant in August 2026.

Shenzhen Suteng has disclaimed liability and is defending the action. As of June 30, 2026, no provision was recognised because it was not practical to estimate the potential effect of these claims.

23 Events occurring after the reporting period

There were no material subsequent events during the period from July 1, 2026 to the approval date of the Interim Financial Information by the Board on August 26, 2026.

DEFINITIONS AND GLOSSARY

In this interim report, unless the context otherwise requires, the following expressions and terms shall have the meanings set out below:

"ADAS"	advanced driver assistance systems, the groups of electronic technologies that assist drivers in driving and parking functions; it also refers to levels 1 to 3 autonomous driving as defined by the Society of Automotive Engineers
"AI"	artificial intelligence
"Audit Committee"	the audit committee of the Company
"Auditor"	PricewaterhouseCoopers, the independent auditor of the Company
"automotive OEMs" or "OEMs"	original equipment manufacturer, which assembles and installs automotive parts during the construction of a new vehicle
"Board"	the board of Directors of the Company
"Chief Executive Officer"	the chief executive officer of the Company
"Company" or "our Company" or "the Company"	RoboSense Technology Co., Ltd (速騰聚創科技有限公司), an exempted company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 2498)
"Corporate Governance Code" or "CG Code"	Corporate Governance Code, as set out in Appendix C1 to the Listing Rules
"Director(s)"	director(s) of the Company
"Dr. Qiu"	Qiu Chunxin (邱純鑫), our co-founder, chairman of the Board, executive Director and chief scientist of our Company
"Dr. Zhu"	Zhu Xiaorui (朱曉蕊), our co-founder, non-executive Director and scientific advisor of our Company

"FOV"	the field of view
"Global Offering"	the Hong Kong public offering and the international offering of the Company, details of which are set out in the Prospectus
"Group" or "our Group" or "the Group" or "RoboSense" or "we" or "us" or "our"	the Company and its subsidiaries from time to time
"HKD" or "HK$"	Hong Kong Dollars, the lawful currency of Hong Kong
"Hong Kong"	Hong Kong Special Administrative Region of the PRC
"IFRS"	IFRS Accounting Standards, which include standards, amendments and interpretations promulgated by the International Accounting Standards Board and interpretation issued by the International Accounting Standards Committee
"Latest Practicable Date"	September 18, 2026, being the latest practicable date for the purpose of ascertaining certain information in this interim report prior to its publication
"LiDAR"	a remote sensing method that uses light to measure the distance or range of objects
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Listing Date"	January 5, 2024, the date on which our Shares are listed on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"MEMS"	the micro-electromechanical system, a semiconductor product that has both mechanical and electronic components, typically on a chip
"Model Code"	Model Code for Securities Transactions by Directors of Listed Issuers, as set out in Appendix C3 to the Listing Rules

"Mr. Liu"	Liu Letian (劉樂天), our co-founder, executive Director and chief technology officer of our Company
"Mr. Qiu"	Qiu Chunchao (邱純潮), our executive Director and Chief Executive Officer
"perception solution"	visual, LiDAR or fusion solution that provides perception capabilities based on information collected from cameras, LiDARs or other sensors
"Post-IPO Share Incentive Scheme"	the post-IPO share incentive scheme of the Company adopted and approved by the Shareholders with effect from June 29, 2023, the principal terms of which are set out in Prospectus. The maximum aggregate number of Shares which may be issued pursuant to all awards to be granted after Listing under the Post-IPO Share Incentive Scheme shall not exceed 21,000,000 Shares or a lesser number of Shares as determined by the Board (the "**Scheme Mandate Limit**"). The Post-IPO Share Incentive Scheme is subject to Chapter 17 of the Listing Rules
"PRC" or "Mainland China" or "China"	the People's Republic of China, which, for the purpose of this interim report and for geographical reference only, excludes Hong Kong, Macau Special Administrative Region of the PRC and Taiwan
"Pre-IPO Share Incentive Scheme A"	the pre-IPO share incentive scheme of the Company adopted and approved by the then Shareholders with effect from December 30, 2021, the principal terms of which are set out in the Prospectus
"Pre-IPO Share Incentive Scheme B"	the pre-IPO share incentive scheme of the Company adopted and approved by the then Shareholders with effect from December 30, 2021, the principal terms of which are set out in the Prospectus
"Prospectus"	the prospectus of the Company dated December 27, 2023 in relation to the Company's Global Offering and Listing
"Reporting Period"	the six months ended June 30, 2026

"RMB"	Renminbi, the lawful currency of the PRC
"R&D"	research and development
"Securities and Futures Ordinance" or "SFO"	Securities and Futures Ordinance, Chapter 571 of Laws of Hong Kong
"Share(s)"	the ordinary share(s) in the share capital of the Company
"Shareholder(s)"	the holder(s) of Share(s)
"Shenzhen Suteng"	Suteng Innovation Technology Co., Ltd. (深圳市速騰聚創科技有限公司), a company incorporated under the laws of the PRC on August 28, 2014, and an indirectly wholly-owned subsidiary of the Company
"SoC"	systems on a chip
"SOP"	start of production, which signifies the transition from the development and testing phase to manufacturing and commercialization, when the product is ready for mass production and delivery
"SPAD"	the single-photon avalanche diode, a photodetector within the same family as photodiodes and avalanche photodiodes, while also being fundamentally linked with basic diode behaviors
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed to it under the Listing Rules
"Tier 1 supplier"	a company that supplies parts or systems directly to automotive OEMs
"Treasury Share(s)"	has the meaning ascribed to it under the Listing Rules
"U.S. dollar(s)" or "USD"	United States dollars, the lawful currency of the United States of America

In this interim report, certain amounts and percentage figures included have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them. Any discrepancies in any table or chart between the total shown and the sum of the amounts listed are due to rounding.

DEFINITIONS AND GLOSSARY

For ease of reference, the names of the PRC established companies or entities, governmental authorities, institutions, natural persons, laws or regulations have been included in this interim report in both the Chinese and English languages and in the event of any inconsistency, the Chinese versions shall prevail. English translation of the official Chinese names are for identification purpose only.

This interim report contains certain forward-looking statements. These forward-looking statements are based on information currently available to the Group or the current belief, expectations and assumptions of the Board. These forward-looking statements are subject to risks, uncertainties and other factors beyond the Company's control which may cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. In light of the risks and uncertainties, the inclusion of forward-looking statements in this report should not be regarded as representations by the Board or the Company that the plans and objectives will be achieved, and Shareholders and investors of the Company should not place undue reliance on such statements.